Spatial distribution and modulation of nitric oxide synthase in a hypertensive rat model by Yannaccone, Andrew
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2012
Spatial distribution and modulation of nitric oxide
synthase in a hypertensive rat model
Andrew Yannaccone
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Physiology Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/2649
School of Medicine
Virginia Commonwealth University
This is to certify that the dissertation prepared by Andrew T. Yannaccone entitled
SPATIAL DISTRIBUTION AND MODULATION OF NITRIC OXIDE SYNTHASE
IN A HYPERTENSIVE RAT MODEL has been approved by his or her committee as
satisfactory completion of the dissertation requirement for the degree of Doctor of
Philosophy.
Dr. Roland N. Pittman; VCU School of Medicine
Dr. Sheryl Finucane; VCU School of Allied Health Professions
Dr. Rakesh C. Kukreja; VCU School of Medicine
Dr. Paul H. Ratz; VCU School of Medicine
Dr. Mary S. Shall; VCU School of Allied Health Professions
Dr. Diomedes E. Logothetis; Chair, Department of Physiology & Biophysics, VCU School of Medicine
______________________________________________________________________________________
Dr. Jerome F. Strauss III; Dean, VCU School of Medicine
Dr. F. Douglas Boudinot, Dean of the Graduate School
February 6, 2012
2
© Andrew T. Yannaccone, 2012
All Rights Reserved
ii
SPATIAL DISTRIBUTION AND MODULATION OF NITRIC OXIDE SYNTHASE
IN A HYPERTENSIVE RAT MODEL
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
by
ANDREW T. YANNACCONE
BS, Health Science, Misericorida University, 2002
MSPT, Physical Therapy, Misericordia University, 2002
Director: DR. ROLAND N. PITTMAN
PROFESSOR
DEPARTMENT OF PHYSIOLOGY & BIOPHYSICS
Virginia Commonwealth University
Richmond, Virginia
February 2012
iii
Acknowledgement
Any doctoral student would (and should!) agree that the journey to a PhD is
seldom, if ever, one the student makes alone.  Indeed, I would not be where I am today
were it not for the tireless love, support and encouragement of my friends, family,
professional peers and colleagues.  Truth be told, words alone cannot express the depth of
my gratitude.  Fortunately, I share a connection with many of these wonderful individuals
that goes beyond words.  To all of you I offer a deeply heartfelt and sincere “Thank you”!
I will now endeavor to list many of those that made this unforgettable journey
with me by name.  First and foremost, I would like to acknowledge and thank my
advisor, Dr. Roland N. Pittman, whose gentle humor, patience, generosity and devotion
to the science of physiology made my experience in his laboratory unforgettable and a
sincere pleasure; my parents Tom and Kay; my sister Adria; my grandparents Donald,
Robert, Dorothy and Virginia; my little angel Junebug; all of my aunts, uncles, cousins
and other extended family members (I love you all!); my better half Kevin Norfleet and
family; steadfast and patient friends, both old and new and in no particular order,
including Dr. Melissa Bednarek, Dr. Janine Firmender and family, Olivia Cornell,
Gabriel Mullins, Connie Quinn, Christine Luhrs German, Jason Tuminski, Chris Scarba,
Jason Polovchik, Ken Nguyen, David Measel, Jason and Kirsten (Peterson) Ditzler,
Sharon Schroeder and family, Dr. Bill and Mrs. Janet Baedke, Diane Souders Martin, Dr.
Michael and Mr. Robert Tian, Ann Maddox, Marshall Vogt, Dominique Sautron, James
iv
Spencer, Amanda Claggett, Michael Ny, Dr. Danny Jaek, Matt Hupp, Alex Bonilla,
Donnie Page, Allison Behm Pugh, Amy Hyser Mundis, Robert and Andrea Criswell,
Austin Ratliff, Ryan White, Avanti Kollaram, Chris Corday, Chris Davis, Darrell Coffey,
Field Sexton, Phoebe Dacha, Frank Kosnosky Jr., Jenny McNamara, Dr. Kelly Stinelli
Lindenberg, Charlie and Kristen (Chaffins) Kelly, Laura Evelyn Spafford, Tom Winn,
Mary Kay  and Alex Vasold, Amanda McGuire, Michelle Bailey and family, Kristin
Simmons, Mary Alice Lachman, Matt and  Paulann Buczek, Michelle Pfeiffer, Miranda
Walker, Norma Briggs Bear, Patricia Brameld Genet, Preston Davis, Quang Nguyen, Dr.
Sam Campbell, Sarah Rome, Steven Thai, Michael and Vanessa Anderson and Dr. Will
Case.
I would like to thank my physical therapy professional peers, both past and
present, including (but not limited to) Mark Bouziane, the entire rehabilitation services
team at Retreat Doctors’ Hospital and the entire rehabilitation staff at Lancaster General
Hospital (2003-2006).  I owe a special “thank you” to Dr. Dixie Bowman – my
experience in your classroom re-affirmed my love for teaching the art and science of
physical therapy.
There are current and past members of the Pittman lab that deserve special
mention for their significant contributions to the success of my project.  Dr. Bjorn Song:
your surgical skills are invaluable – thank you for sharing them with me.  Dr. Helena
Carvalho:  I enjoyed our trip to New Orleans together, cancelled flights and all.  Thank
vyou for all of the good conversation, encouragement and support!  Dr. Alex Golub:  thank
you for your frank, thoughtful and very helpful comments on my project through the
years.  Dr. Matt Barker:  thank you for the support and helping me settle into the lab.
Sirish Nama, Hiyab Yohannes, Jessica Webb and Heather Hammond:  I hope I was able
to offer some tidbits of “graduate student wisdom” to all of you.  Best of luck in your
future endeavors.
My dissertation committee, comprised of talented faculty from the Schools of
Medicine and Allied Health, provided me with guidance, assistance and inspiration,
without which I would not be where I am today.  My heartfelt gratitude to Dr. Rakesh
Kukreja and his entire lab, with special thanks to Dave Durrant and Dr. Anindita Das; Dr.
Paul Ratz and his talented lab manager (and my friend) Amy S. Miner; Dr. Mary Shall:
many, many thanks for allowing me to use your equipment and for the many hours you
spent patiently instructing me in the techniques at which you are so adept; and Dr. Sheryl
Finucane, to which I owe a huge debt of gratitude for your guidance and suggestions for
sources of extramural funding and physical therapy faculty positions.
Finally, there are several members of the Department of Physiology &
Biophysics, the School of Medicine and the Virginia Commonwealth University
community at large that I would like to thank, including:  Dr. George Ford, Dr. Clive
Baumgarten, Dr. John Povlishock and lab (especially John Greer), Debbie Bohn, Dr.
Linda Costanzo, Dr. Diomedes Logothetis, Christina Meliagros, Dr. Scott Henderson,
vi
Natasha Purdie, Dr. Sid Ghosh and Sarah Reese.  Finally, I would like to recognize Dr.
Aleksander Popel at Johns Hopkins University for his thoughts on my project through the
years.
Unfortunately, no matter how hard I try, I am certain I have neglected to include a
few names in the above.  Please accept my apologies as your contributions were just as
valuable as those from the individuals mentioned above.  And again:  thank you to all!
vii
Table of Contents
Page
Acknowledgements ............................................................................................................ iii
List of Tables .................................................................................................................. xiii
List of Figures ................................................................................................................... xv
Abstract ................................................................................................................ xviii
Chapter
1 INTRODUCTION ............................................................................................... 1
Overview ...................................................................................................... 1
Properties of Nitric Oxide (NO) ................................................................... 2
Distribution and Sources of NO ................................................................... 4
Characteristics of Nitric Oxide Synthase (NOS) Isoforms........................... 6
Non-Enzymatic Sources of NO .................................................................... 9
Biological Roles of NO .............................................................................. 11
NO Concentration in vivo and the “NO Paradox” ...................................... 12
The “L-arginine Paradox” .......................................................................... 14
Hypertension Definition and Causes .......................................................... 16
Hypertension and the Metabolic Syndrome ............................................... 20
NO, Lipid Rafts and Redox Signaling........................................................ 22
NOS “Uncoupling”..................................................................................... 27
NOS Downregulation ................................................................................. 30
Specific Roles of sGC and cGMP .............................................................. 32
viii
Capillarity and Rarefaction in Skeletal Muscle Tissue .............................. 33
Fiber Type Nomenclature ........................................................................... 38
Goals of the Project and Conclusion .......................................................... 40
2 MATERIALS AND METHODS.................................................................... 42
Experimental Animal Preparation .............................................................. 42
Immunohistochemical (IHC) Protocol for Detection of NOS in Skeletal
Muscle Tissue ....................................................................................... 43
IHC Typing of Skeletal Muscle Fibers....................................................... 45
IHC Staining for Endothelial Cells in Skeletal Muscle Tissue using Alkaline
Phosphatase Protocol ............................................................................ 46
Microscopic Analysis of IHC Staining....................................................... 47
General Procedures and Procedures for NOS 1/2 Image Acquisition .. 47
Grading of NOS1 Images ..................................................................... 48
Examination of NOS2 Images .............................................................. 48
Myosin Heavy Chain (MHC) Skeletal Muscle Fiber-typing Acquisition
Protocol................................................................................................. 49
NOS3 Image Acquisition Protocol ....................................................... 50
Examination of NOS3 Images .............................................................. 50
Image Acquisition Protocol for Endothelial Cells in Skeletal Muscle
Tissue Capillaries via Alkaline Phosphatase staining .......................... 50
Capillary Counting Protocol ................................................................. 50
Western Blot Analysis of NOS Isoforms in Skeletal Muscle Tissue ......... 51
ix
Tissue Preparation ................................................................................ 51
Total Protein Concentration Determination via the Bradford Method . 52
Gel Electrophoresis Protocol ................................................................ 52
Nitrocellulose Transfer Protocol .......................................................... 52
Probing of Membrane ........................................................................... 53
Electrophoresis Gel Analysis of MHC Isoforms in Skeletal Muscle Tissue54
Tissue Preparation ................................................................................ 54
Electrophoresis Stock Solutions ........................................................... 54
Gel Electrophoresis Running Buffers ................................................... 56
Total Muscle Protein Assay.................................................................. 56
Gel Preparation and Casting ................................................................. 56
Muscle Sample Preparation .................................................................. 57
Assembly of Electrophoresis Apparatus............................................... 57
Running Conditions.............................................................................. 58
Processing............................................................................................. 58
Statistics................................................................................................ 58
3 RESULTS ....................................................................................................... 60
Rat Subjects ................................................................................................ 60
MHC Determinations ................................................................................. 63
MHC Distributions ............................................................................... 63
Examples of Images Collected......................................................... 64
Fiber Type Distribution Statistics.................................................... 70
xAnalysis of MHC Isoform Expression by Gel Electrophoresis ....... 72
MHC Fiber Geometric Data ....................................................................... 77
Fiber Cross-sectional Area ................................................................... 77
Fiber Perimeter ..................................................................................... 77
Minimum Fiber Diameter ..................................................................... 77
Maximum Fiber Diameter .................................................................... 77
Min/Max Fiber Diameter Ratio ............................................................ 78
Minor Elliptical Fiber Diameter ........................................................... 78
Major Elliptical Fiber Diameter ........................................................... 78
Minor/Major Elliptical Diameter Ratio ................................................ 78
Alkaline Phosphatase Staining to Reveal Capillary Endothelium.............. 81
Co-localization Studies of Nitric Oxide Synthase Isoforms....................... 85
Nitric Oxide Synthase 1........................................................................ 85
Nitric Oxide Synthase 2........................................................................ 89
Nitric Oxide Synthase 3........................................................................ 92
Co-localization of NOS3 and Alkaline Phosphatase Staining for
Capillary Endothelium.......................................................................... 95
Western Blot Analysis of NOS Isoforms ............................................. 97
4 DISCUSSION ............................................................................................... 102
Summary of Results.................................................................................. 102
Overview ............................................................................................ 102
Fiber Type Populations....................................................................... 102
xi
Morphometry of Fiber ........................................................................ 103
Basic Fiber Geometry.................................................................... 103
Elliptical Fiber Geometry.............................................................. 103
Capillarity...................................................................................... 103
NOS Expression ............................................................................. 104
Immunohistochemistry.............................................................. 104
Western Blot ............................................................................. 104
Animal Subjects........................................................................................ 104
Age...................................................................................................... 104
Mean Arterial Pressure ....................................................................... 105
Classification of Fibers ............................................................................. 106
Fiber Type Population Distributions By............................................. 106
Fiber Count versus Cross-sectional Area ..................................... 106
MHC Content via Gel Electrophoresis.......................................... 110
Fiber Morphometry ....................................................................... 111
Indices of Fiber Shape.............................................................. 111
Minimum Fiber Diameter ......................................................... 111
Maximum Fiber Diameter ........................................................ 112
Cross-sectional Area ................................................................ 112
Perimeter .................................................................................. 112
Capillarity ................................................................................................. 112
NOS Expression via Immunohistochemistry ........................................... 115
xii
Isoform Location by Fiber Type......................................................... 115
NOS1 in Type I skeletal muscle fibers in the spinotrapezius.... 115
NOS2 in Type IIA/B fibers ............................................................. 117
NOS3 Association with Capillary Endothelium ............................ 118
Co-localization of NOS3 staining with alkaline phosphatase staining
for capillary endothelium ................................................................... 120
Limitations of Immunohistochemical Technique ........................... 121
NOS Expression via Western Blot ........................................................... 123
Expression of NOS Isoforms.............................................................. 123
Use of alpha-tubulin as loading control.............................................. 124
Consistency of Results between Blots................................................ 124
Overall Conclusions ................................................................................. 125
Purpose of Study................................................................................. 125
Important Connections ....................................................................... 126
Recommendations for Future Studies....................................................... 128
References ....................................................................................................................... 129
Appendices ...................................................................................................................... 151
A NOSI / Type I Fiber Co-localization Image Grading Instruction Sheet ....... 151
B Mean Numeric Staining Grade for NOS1 / Type I Fibers in Practice (WKY)
Subjects Figure ......................................................................................... 153
C Summary Statistics for Practice Numeric Staining Grades........................... 154
xiii
List of Tables
Page
Table 1: Summary Statistics for Rat Subjects Used In IHC Experiments. ....................... 62
Table 2: Summary Statistics for Rat Subjects Used in WB and MHC Gel Electrophoresis
Experiments....................................................................................................................... 62
Table 3: Summary Statistics for Percent Fiber Population (Fiber Count Basis)............... 71
Table 4: Summary Statistics for Percent Fiber Population (Total Cross-sectional Area
Basis)................................................................................................................................. 71
Table 5: Summary Statistics for Intensity of MHC Isoform Bands in WKY versus SHR
Subjects. ............................................................................................................................ 73
Table 6: Summary Statistics for Intensity of MHCIsoform Bands Within Strains........... 73
Table 7: Summary Statistics for Basic MHC Fiber Geometric Data. ............................... 79
Table 8: Summary Statistics for MHC Fiber Elliptical Data. ........................................... 80
Table 9: Summary Statistics for Capillarity...................................................................... 82
xiv
Table 10: Summary Statistics for Experimental Numeric Staining Grades...................... 86
Table 11: Summary Statistics for Co-localization of NOS3 and Alkaline Phosphatase
Staining for Capillary Endothelium. ................................................................................. 96
Table 12: Summary Statistics for Nitric Oxide Synthase 1-3 in WKY and SHR Strains as
Determined by Western Blot #1........................................................................................ 98
Table 13: Summary Statistics for NOS1-3 in WKY and SHR Strains as Determined by
Western Blot #2................................................................................................................. 98
xv
List of Figures
Page
Figure 1: Representative image of Type I fiber staining in WKY rat............................... 64
Figure 2: Representative image of Type I fiber staining in SHR...................................... 65
Figure 3: Representative image of Type IIA fiber staining in WKY rat .......................... 66
Figure 4: Representative image of Type IIA fiber staining in SHR ................................. 67
Figure 5: Representative image of Type IIB fiber staining in WKY rat........................... 68
Figure 6: Representative image of Type IIB fiber staining in SHR.................................. 69
Figure 7: Representative image of MHC bands in WKY rat ............................................ 74
Figure 8: Representative image of MHC bands in SHR ................................................... 74
Figure 9: Mean Type I vs. IIa vs. IIb MHC Protein Intensity in WKY rat ....................... 75
Figure 10: Mean Type I vs. IIa vs. IIb Myosin Heavy Chain Protein Intensity in SHR... 76
xvi
Figure 11: Representative image of alkaline phosphatase staining for capillary endothelium
in WKY rat........................................................................................................................ 83
Figure 12: Representative image of alkaline phosphatase staining for capillary endothelium
in SHR............................................................................................................................... 84
Figure 13: Representative image of NOS1 staining in WKY rat...................................... 87
Figure 14: Representative image of NOS1 staining in SHR............................................. 88
Figure 15: Representative image of NOS2 staining in WKY rat...................................... 90
Figure 16: Representative image of NOS2 staining in SHR............................................. 91
Figure 17: Representative image of NOS3 staining in WKY rat ...................................... 93
Figure 18: Representative image of NOS3 staining in SHR............................................. 94
Figure 19: Representative protein band images of A) alpha-tubulin (52 kDa), B) NOS1
(165 kDa), C) NOS2 (130 kDa) and D) NOS3 (140 kDa) in Western Blots .................... 99
Figure 20: NOS1 (NOS1) vs. NOS2 vs. NOS3 in WKY and SHR (Blot #1)................. 100
xvii
Figure 21: NOS1 vs. NOS2 vs. NOS3 in WKY and SHR (Blot #2) .............................. 101
xviii
Abstract
SPATIAL DISTRIBUTION AND MODULATION OF NITRIC OXIDE SYNTHASE IN
A HYPERTENSIVE RAT MODEL
By Andrew T. Yannaccone, P.T., Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Major Director: Dr. Roland Pittman
Professor, Department of Physiology & Biophysics
There are gaps in the fundamental understanding of the expression of nitric oxide
synthases (NOS) in the microvasculature. We examined co-localization of NOS1 (nNOS),
NOS2 (iNOS) and NOS3 (eNOS) in the spinotrapezius muscle of young adult male
Wistar-Kyoto (WKY) and Spontaneously Hypertensive (SHR) rats according to fiber type
using immunohistochemistry and brightfield microscopy.  Data regarding fiber
distribution, population and morphology data were collected.  Alkaline phosphatase
staining was used to determine capillary density and average number of capillaries around
xix
a fiber.  Gel electrophoresis and Western blot techniques were used to compare myosin
heavy chain (MHC) protein expression with fiber type population data and to determine
NOS1-3 protein expression in whole muscle homogenate.  This study should provide a
more accurate understanding of differences in NOS expression between these two strains
of rats.
1INTRODUCTION
Overview: The relationship between nitric oxide (NO), the enzyme that produces
it, nitric oxide synthase (NOS), and hypertension has been the subject of much recent
research.  There is a large volume of literature dealing with this very broad topic so this
chapter will attempt to elucidate the current scientific understanding about the relationship
between impaired NO production/bioavailability and hypertension, as well as the
significance of co-localization of various NOS isoforms within specific skeletal muscle
fiber types.  This will be accomplished by giving an overview of nitric oxide synthase
nomenclature, structure and regulation, followed by a review of the numerous
physiological and patho-physiological roles that NO is implicated in playing in mammalian
animal species.  Special attention and discussion will be given to the so-called “NO and L-
arginine paradoxes” as well as NOS uncoupling, as they may be implicated in the
pathogenesis of hypertension.  Next, the pathogenesis and clinical presentation of
hypertension in humans will be discussed.  The specific role of NO in hypertension, as it is
currently understood in the literature, will then be discussed thoroughly, but concisely.
The goal of this introduction is to impart to the reader a clearer understanding of the
complex relationships among NOS, NO, skeletal muscle fiber type and hypertension.
2Given the voluminous amount of scientific literature on NO, only the properties of
NO most relevant to the pathogenesis and presentation of hypertension will discussed here,
so as to establish a clear link between the two.  Therefore, brief answers to each of the
following questions regarding NO will be discussed in turn: “What is NO?”, “Where does
NO come from?”, “What does NO do under normal physiological conditions?”, “What are
the “NO and L-arginine paradoxes”, “What is the significance of NOS co-localization
within certain skeletal muscle fiber types?”
Finally, capillarity and the phenomenon known as “rarefaction” will be discussed
and a brief review of skeletal muscle fiber-typing methods will be presented.
Properties of Nitric Oxide: Nitric oxide, which was initially known as
endothelium-derived relaxing factor (EDRF), is a gaseous, lipophilic, free radical, bio-
messenger molecule found in mammalian cells.  There are numerous NO species,
including NO• [this is the specific free radical species of nitric oxide (with an unpaired
electron) that is designated by the notation “NO” in this dissertation], NO+ (nitrosonium),
NO- (nitroxyl), ONOO- (peroxynitrite, which is the byproduct of the reaction of NO with
superoxide), NO2 (nitrogen dioxide), N2O3 (dinitrogen trioxide), and NO2+ (nitronium).
Clearly, one must exercise caution when talking about “nitric oxide,” as each NO species
plays unique roles in normal and patho-physiology.
Nitric oxide is a free radical with eleven valence electrons.  As such it participates
in numerous, rapid reactions in vivo, including activation of soluble guanylate cyclase
(sGC), scavenging by hemoglobin and oxidation by superoxide (Beckman and Koppenol
31996, Condorelli and George 2001).  NO that has not been consumed by the
aforementioned reactions can  produce autocrine and paracrine effects (through enzymatic
sources) and endocrine effects (through non-enzymatic sources) and NO has been
implicated in the maintenance of vessel wall function and structural integrity (Lane and
Gross 2002, Cattaruzza et al. 2005, Sonveaux et al. 2006, Chen et al. 2008).  Indeed, Chen
et al. suggest that paracrine NO is responsible for basic homeostasis under basal conditions
while endocrine NO contributes to hypoxic vasorelaxation (Chen et al. 2008).
Furthermore, NO is in equilibrium with more stable nitrogen oxide-derived species in
living systems and the interconversion of these species is regulated by chemical constraints
and enzymes (Sonveaux et al. 2006).
How then does this simple molecule exert the numerous effects attributed to it?
Responses to NO, like those that will be discussed in more detail later in this chapter, are
primarily mediated by S-nitrosylation of cysteine redox centers or by coordinated, covalent
interactions with heme [such as is found in cytochrome c oxidase and soluble guanylate
cyclase (sGC)] or non-heme iron and copper.  Ion channels, receptors, enzymes,
transcription factors and small G-proteins all possess S-nitrosylation motifs, suggesting
that all of these structures can be acted upon by NO in some fashion (Stamler and Meissner
2001).  The variety of targets mentioned above reinforces the need, whenever discussing or
reading literature about NO, for one to keep in mind that NO has numerous targets and that
the location of interaction between NO and its target, as well as local NO concentrations,
duration of exposure and concentrations of reaction byproducts, are important to a clear
understanding of NO’s effects in a particular tissue.
4Distribution and Sources of NO: As mentioned earlier, the distribution of NO is
extremely important when investigating NO’s role in a particular tissue or biological
process.  This is especially true when investigating how NO affects vascular relaxation. In
vivo experimental measurements using electrochemical methods to detect NO generally
report perivascular NO concentrations (CNO) between 200 and 1,000 nM under control
conditions (Chen et al. 2008).  On the other hand, in silico models of endothelial cells,
constructed by theoreticians using data collected from other investigators, have predicted
NO concentrations of ~100 nM near an arteriole (Chen et al. 2008).  The role of NO
distribution, especially involving NO’s interactions with other molecules, will be discussed
in more detail later in this chapter.
Nitric oxide can be supplied to a biological system both endogenously and
exogenously and endogenous NO comes from both enzymatic and non-enzymatic sources.
The endogenous enzymes that produce NO are referred to as nitric oxide synthases (NOS).
These enzymes, which possess an amino-terminal oxidase domain and a carboxy-terminal
reductase domain, utilize L-arginine, in the presence of molecular oxygen, nicotinamide
adenine dinucleotide phosphate (NADPH) and the coenzyme tetrahydrobiopterin (BH4) to
produce equimolar amounts of L-citrulline and NO through a series of redox reactions with
N-hydroxyl-L-arginine produced as an intermediate product.  Currently, three NOS
isoforms have been definitively indentified.  These isoforms are named after the tissues in
which they were originally discovered and include neuronal NOS (NOS1 or nNOS),
inducible NOS (NOS2 or iNOS) and endothelial NOS (NOS3 or eNOS).  The numerical
5designations – NOS 1, NOS2 and NOS3 – correspond to the order in which they were
discovered.
It should be noted, however, that NOS1 is also expressed in cardiac muscle and
endothelial cells (Lacza et al. 2006), in the sarcolemma, cytosol and in the costomeres
interposed by unstained membrane segments of the muscle fibers of hamster, human, rat
and mouse muscle tissue (Segal et al. 1999, Frandsen et al. 2000, Punkt et al. 2002, Rothe
et al. 2005), as well as around arterioles (Huang et al. 2002, Kashivagi et al. 2002,
Talukder et al. 2004).  Frandsen et al. also demonstrated stronger NOS1 staining in Type I
fibers versus Type II fibers (Frandsen et al. 2000).  Furthermore, Rothe et al. suggested
that some NOS1 was associated with the outer membrane of the mitochondria in rat
skeletal muscle tissue (Rothe et al. 2005).  An investigation by Punkt et al. demonstrated
the presence of NOS2 in Type I, IIA and IIB fibers of rat skeletal muscle while NOS3
appears to be expressed only in vascular endothelial cells (Punkt et al. 2002).  NOS3 also
produces NO in response to shear stress, acetylcholine (ACh), bradykinin, histamine,
purines, leukotrienes and endothelin (in smooth muscle and the endothelial cell layer) and
is regulated by numerous factors such as sub-cellular location, protein-protein interactions,
phosphorylation at Ser1179 in the reductase domain and de-phosphorylation at Thr495 in
the calmodulin (CaM) binding domain (which increases the enzyme’s activity) and
availability of obligate cofactors (Förstermann et al. 1998, Kähler et al. 2000 and 2001,
Mitchell et al. 2001, Shah and Singh 2006, Singh et al. 2007, Schulz et al. 2008).
6The existence of a fourth, calcium-dependent NOS isoform, mitochondrial NOS or
mtNOS, is still a matter of debate.  For the sake of completeness, this debate will be
reviewed very briefly later in this chapter.
Characteristics of NOS Isoforms: NOS1 and NOS3 are constitutively active,
calcium/calmodulin (Ca2+/CaM)- dependent and are considered low-output producers of
NO under basal conditions. NOS3, in particular, is considered the major source of NO
regulating vascular tone (Lacza et al. 2006, Chen et al. 2008) and has even been shown to
react with nitrite under anoxic conditions (Gautier et al. 2006).  Calmodulin is a
ubiquitous, calcium-binding protein that binds to numerous protein targets and regulates
several processes, including inflammation, metabolism and apoptosis, among others.
Calmodulin reversibly binds with NOS1 and NOS3 through changes in intracellular Ca2+
concentration.  In the case of NOS2, however, calmodulin is permanently and tightly
bound to the enzyme.  In all three NOS isoforms the role of calmodulin is to bind to the
protein linker connecting the reductase and oxidase domains, thereby regulating the
activity of the enzyme by activating flavin mononucleotide (FMN)-to-heme electron
transfer (Daff 2003).
NOS2 is unique in several ways.  Its expression in macrophages is controlled at the
gene transcription level, its activity is Ca2+ -independent and it is considered a high-output
enzymatic source of NO (Lane and Gross 2002).  NOS2 is involved in the immune
system’s response to inflammatory and pro-inflammatory mediators such as cytokines,
bacterial components, lipopolysaccharide, IFN-γ, IL-1β and TNF-α and may be expressed
7after ischemia-reperfusion injury (Lacza et al. 2006).  Interestingly, in 2006, Kleinbongard
et al. reported the existence of a functional form of NOS3 in erythrocytes (Kleinbongard et
al. 2006), but this finding has been repudiated by data from other groups (Hilarius et al.
2007).  It should also be noted that without a protective mechanism, any NO produced
from this enzymatic source would be rapidly scavenged by hemoglobin.  Indeed, Joshi et
al. demonstrated that this consumption of intraluminal NO does indeed take place (Joshi et
al. 2002).  Although it is unclear how physiologically relevant NO from this source is, it
has been suggested that blood-borne NO bioactivity is a key mechanism for matching
blood flow to the metabolic activity of local tissue (Chen et al. 2008).  Finally, in an
interesting 1996 study by Gath et al., the authors presented evidence suggesting the
presence of a “constitutive” NOS2 isoform in guinea pig skeletal muscle, confirming
earlier reports of NOS2 expression in normal tissues (Morrissey et al. 1994, Gath et al.
1996)
Two other enzymatic sources of NO are worth noting here.  The enzyme xanthine
oxidoreductase functions by reducing nitrite, also a non-enzymatic source of NO, via an
acid-catalyzed mechanism.  The other enzymatic source is cytochrome P450 reductase,
which reduces nitrate to nitrite, which is then reduced to NO by cytochrome P450.
Numerous arguments against the existence of a mitochondrial NOS isoform have
been offered, including the lack of a NOS-like sequence in the mitochondrial genome
(meaning the enzyme must be imported into the mitochondrion), lack of a mitochondrial
transport signal in the sequences of the known NOS isoforms, potential lack of obligate
NOS cofactors in the mitochondrial matrix, lack of L-arginine as a substrate and the
8presence of agmatine, which is the product of arginine decarboxylase and a known NOS
inhibitor.  Furthermore, results demonstrating the presence of a mitochondrial NOS
isoform have not been confirmed by complementary methods and have been difficult to
reproduce, possibly due to minute mtNOS concentrations and contamination of
experimental samples.
At this point it is important to note that investigators have detected a number of
NOS splice variants.  Four NOS1 splice variants have been identified to date, designated
nNOSβ, nNOSγ, nNOSµ and nNOS-2 (Note:  NOS splice variant designations per
Alderton et al. 2001). While the regulation and biological significance of these NOS splice
variants is poorly understood, nNOSµ is the predominant isoform expressed in rat skeletal
muscle and the most extensively characterized NOS1 splice variant (Silvagno et al. 1996,
Alderton et al. 2001).  nNOS-2 has been detected in mouse brain and human
neuroblastoma cell lines and has been implicated as a dominant negative regulator of
NOS1 activity (Ogura et al. 1993, Fujisawa et al. 1994, Brenman et al. al 1997, Alderton et
al. 2001).  Little is known about NOS2 splice variants, however, mRNA transcripts have
been detected in human epithelial cells, alveolar macrophages and endothelial kidney 293
cells (Alderton et al. 2001).  Finally, no evidence currently exists for NOS3 splice variants
(Alderton et al. 2001).
Some novel solutions to the aforementioned problems were proposed by Lacza et
al. in a 2006 review of the current scientific literature both supporting and challenging the
existence of mtNOS (Lacza et al. 2006).  The Lacza group hypothesized that perhaps a
mtNOS-like oxygenase enzyme uses the electron transport chain as an electron source
9instead of its own reductase domain.  There is, however, absolutely no experimental
evidence to support this hypothesis.  Lacza et al. offered the hypothesis that NOS3 is
actually attached to the outer mitochondrial membrane, which would negate concerns
about transport and folding of NOS proteins as well as required cofactors for NOS function
not being present in the mitochondrial matrix (Lacza et al. 2006).  Data supporting this
hypothesis have been provided by two separate groups (Henrich et al. 2002, Gao et al.
2004).  Finally, mitochondrial nitrosothiols including nitrated tyrosine residues and S-NO-
glutathione may be the source of the mitochondrial NO, although this hypothesis has
limited plausibility since such a synthetic pathway would require exogenous sources of NO
(Lacza et al. 2006).  Despite the limitations of the three hypotheses discussed above, the
Lacza group concludes their review by suggesting that mitochondria likely do not produce
physiologically relevant levels of NO but rather contribute biologically active nitrates to
the living system (Lacza et al. 2006).
Non-enzymatic Sources of NO: Decreases in tissue O2 tension (PO2) and pH,
either together or separately, can induce production or release of NO from non-enzymatic
sources (Zweier et al. 1999, Singel and Stamler 2004).  It is thought that, when tissue PO2
drops, hemoglobin and glutathione release NO from their storage pools (Singel and
Stamler 2004).  Likewise, decreased tissue pH is thought to cause a release of NO from the
reduction of circulating nitrite by deoxygenated hemoglobin or myoglobin, with the blood
proteins acting as nitrite reductases (Huang et al. 2005, Shiva et al. 2007).  Even iron-
nitrosyl-hemoglobin, the product of deoxyhemoglobin and NO, can rapidly release NO in
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the presence of oxidants (Sibmooh et al. 2007).  These non-enzymatic sources are currently
thought to serve as endocrine sources of NO, however, it is unclear just how much NO is
stored and released from these sources and under what condition(s).  This uncertainty is
due, in part, to the biochemical complexity and lack of direct in vivo measurements of
these reactions (Chen et al. 2008).
Despite the lack of in vivo measurements of NO production from non-enzymatic
sources, computational models of NO release from intraluminal, non-enzymatic sources
predict that 0.25 to 6 pM or ~40 pM NO is delivered to vascular smooth muscle (VSM) by
intraerythrocytic S-nitrosohemoglobin (SNOHb), assuming there is an as yet unknown
protective mechanism to prevent reaction of the NO with scavenging molecules in the
vessel lumen and that the concentration of NO from the luminal nitrite reservoir is about
~40 – 260 pM under physiologic conditions (Chen et al. 2008).  Assuming such a
protective mechanism is absent, the calculated concentration of NO in VSM is about 0.08
pM (Jeffers et al. 2005).  A complete and thorough review of the production, concentration
and distribution of NO from non-enzymatic sources is outside the scope of this
Introduction. However, the reader is referred to an excellent review by Chen et al. (2008)
for further details regarding this important and interesting topic.  What is important to keep
in mind, however, is that it is generally thought that NO derived from endothelial cells acts
in an autocrine manner (Lancaster 1994), while NO derived from non-enzymatic,
intraluminal sources acts in an endocrine manner (Chen et al. 2008).
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Biological Roles of NO: Nitric oxide serves a great number of functions in
biological systems and new roles for this interesting molecule are being discovered all the
time.  A complete review of all of these functions, however concise, is well beyond the
scope of this Introduction.  Instead, the critical role of NO as an activator of sGC in VSM,
which induces vasorelaxation, will be discussed in detail since aberrations in vasomotor
control can lead to a number of pathological conditions, including hypertension.  In
addition to NO’s role as a potent and important vasorelaxant, several other important
functions are worthy of mention, including NO’s ability to decrease mitochondrial O2
consumption via the inhibition of the cytochrome c oxidase enzyme.  Additionally, NO
kills air- and food-borne pathogens (in high concentrations), modulates cardiac
contractility, directs blood flow to ischemic tissues, regulates gastric motility, modulates
glomerular filtration rate, is vasoprotective and is anti-atherogenic.
Nitric oxide affects VSM relaxation via a two-step process.  Upon initially binding
to sGC, a 150-kDa heterodimer consisting of α1 and β1 subunits which contains the same
heme protoporphyrin IX as hemoglobin, NO partially activates the ultra-sensitive enzyme
through the formation of a six-coordinate nitrosyl intermediate (Condorelli and George
2001). Subsequently, this species is converted to a five-coordinate nitroxyl complex
through NO-dependent or NO-independent pathways (Zhao et al. 1999, Condorelli and
George 2001, Tsoukias et al. 2004, Chen et al. 2008).  The concentration of sGC, its
turnover rate and NO concentration work together to determine the rate of cGMP
production (Condorelli and George 2001). Interestingly, the concentration of NO required
for half-maximal activation of sGC (the EC50) has not yet been fully established.  Studies
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investigating the interactions between sGC and NO have demonstrated EC50 values
ranging anywhere from 2.9 to 1,600 nM (Stone and Marletta 1996, Russwurm 1998,
Bellamy et al. 2000, Artz et al. 2001, Roy and Garthwaite 2006, Rodrigues-Juarez 2007,
Chen et al. 2008).  An in silico analysis of sGC kinetics revealed an EC50 of approximate
23 nM (Condorelli and George 2001, Chen et al. 2008). Once produced, NO has a half-life
of approximately one second, allowing it to diffuse both into and out of numerous cells in
some cases (Pacher et al 2007).
NO Concentration in vivo and the “NO Paradox”: If one accepts that the
generally reported perivascular NO concentration values are valid and then considers
reported sGC/NO EC50 values, in experiments conducted in the cellular environment using
endogenous NO, of <10 nM, an apparent paradox arises: if the EC50 is indeed several
nanomolar and perivascular concentrations of NO derived only from the endothelium are
in the several hundred nanomolar range, how, then, is the vasculature regulated, since these
values suggest the smooth muscle tissue would be constantly and maximally relaxed.  This
question is, as yet, unanswered and, in fact, confounded by recent data suggesting that NO
concentrations of less than one nanomolar can trigger maximal vascular relaxation (Kollau
et al. 2005, Chen et al. 2008).
This “NO paradox” may be resolved, at least in part, by further investigation of the
NO-mediated regulation of sGC in smooth muscle.  This regulation, as it is currently
understood, can be mediated by both amplitude- and frequency-dependent mechanisms.
Continuous, low-level (tonic) production forms stable and low-activity sGC heme
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complexes.  Conversely, acute and transient NO production may provide a more efficient
means of sGC activation and can increase cGMP formation sevenfold (Tsoukias et al.
2004, Silva et al. 2007, Chen et al. 2008).  Taken together, these data suggest that it may
be the frequency of NO bursts that limit cGMP formation and regulate vascular tone
(Tsoukias et al. 2004, Chen et al. 2008).
Another intriguing solution to this paradox was suggested in a comprehensive
review of NO and peroxynitrite physiology by Pacher et al. in 2007.  The authors
suggested that erythrocytes serve as a major sink for perivascular NO, requiring the
endothelium to produce 10- to 40-fold more NO than is required to activate sGC within
vascular smooth muscle cells (VSMCs).  It appears likely that this elevated NO production
is what perivascular microelectrodes are detecting.  This measurement, however, is
misleading because it is likely that most of the NO being produced is immediately being
scavenged by circulating erythrocytes.  The authors estimate that the endothelium needs to
produce ~100 nM of NO to achieve a VSMC NO concentration of only 5-10 nM,
concentrations which have been predicted by mathematical models (Pacher et al. 2007).
Although a detailed discussion of NO’s regulation of O2 delivery through its
binding to cytochrome c oxidase is beyond the scope of this Introduction, it is important to
note that NO’s two primary targets, sGC and cytochrome c oxidase, vary in their
sensitivities to NO by a factor of 50.  This implies that the NO-to-cGMP pathway in
smooth muscle tissue would be fully saturated before endothelium-derived NO has a
chance to exert its regulatory effects on mitochondrial respiration in parenchymal cells.
This observation further compounds the “NO paradox” and led Chen et al. to hypothesize
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that there are multiple sources of NO in the perivascular space and that heterogeneity of
NO distribution is an important factor in the regulation of microvascular oxygen delivery
(Chen et al. 2008).  Obviously, further research that accurately and quantitatively
determines the contribution(s) of NO from its numerous sources in the vasculature is
required to resolve this paradox.
The “L-arginine Paradox”: The “L-arginine paradox” is a phenomenon observed
in human subjects in which introduction of exogenous L-arginine results in a transient
increase in NO production.  This is paradoxical because L-arginine concentration in the
cytoplasm of endothelial cells is ~800 µM, which largely saturates NOS3, whose Km to
utilize L-arginine is only 3 µM (Dioguardi 2011, Shin et al. 2011).  This paradox is
important clinically as long-term L-arginine supplementation is ineffective and can result
in deleterious effects on the patient (i.e. persistent ureagenesis), especially those receiving
supplementation to improve vasodilation after myocardial infarction (Chin-Dusting et al.
1996, Schulman et al. 2006, Van de Poll et al. 2007, Dioguardi 2011).
L-arginine regulation and metabolism in human physiology is complex and a
detailed discussion of its role in various metabolic pathways is outside the scope of this
Introduction.  Therefore, the reader is referred to an excellent review on the topic by
Dioguardi (2011).  However, given its clinical significance and relationship to the
production of NO in vivo, a brief discussion of possible explanations for this paradox is
warranted.
One possible explanation for this paradox is discussed in a 2011 study by Shin and
colleagues.  The authors suggest the plasma concentration of L-arginine, ~50-100 µM, may
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play a more crucial role in the explanation for this paradox than previously thought.  The
cationic amino acid transporter 1 (CAT-1) is constitutively active and co-localizes with
NOS3 in caveoli of endothelial cells, suggesting direct delivery of extracellular L-arginine
to NOS3 (Zharikov and Block, 1998, Bednarz et al. 2004).  A 2005 study by Zani et al.
suggests L-arginine transported by CAT-1 is not in rapid equilibrium with the bulk
intracellular L-arginine and that this extracellular L-arginine concentration is crucial to the
mediation of NO release from endothelial cells (Zani et al. 2005, Shin et al. 2011).  Using
an L-arginine ethyl ester that passively diffuses through the endothelial cell membrane,
siRNA to partially silence the CAT-1 transporter and by assaying nitrite/nitrate
concentrations produced by cultured HVECs, Shin et al. (2011) concluded that once L-
arginine is transported into the endothelial cell it no longer has access to the membrane-
bound NOS3 enzyme as noted by the absence of increased NOS3 activity (Shin et al.
2011).  It should be noted that even if one accepts the authors’ conclusions, plasma
concentrations of L-arginine are still well above the reported 3 µM Km for NOS3 to utilize
L-arginine.  Shin et al. suggest that this higher cellular Km value reflects incorporation of
additional rate-limiting steps, including cellular transport, that are not present when
working with purified enzyme (Shin et al. 2011).
Another possible explanation for the “L-arginine paradox” is proposed by
Dioguardi (2011).  The authors suggest that endogenous arginases, which directly compete
for L-arginine and whose activities exceed that of NOS under any conditions, have a Km
100-fold higher and a maximal catalytic rate more than 1,000 times higher than NOS,
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thereby significantly impairing NOS efficiency, especially in the presence of excess
substrate (Wu and Morris 1998, Santhanam et al. 2008).
Study of this puzzling and intriguing paradox continues and results of future studies
in both human and smaller mammalian models should prove interesting.
Hypertension Definition and Causes: According to the American Heart
Association, about one-third of U.S. adults (approximately 73 million) have hypertension
(http://www.americanheart.org/presenter.jhtml?identifier=2114).  Left untreated,
hypertension can lead to a plethora of diseases and conditions, including cerebral vascular
accidents, myocardial infarction, cardiac damage and failure, nephropathy and end-stage
renal disease (amongst others) and mortality
(http://www.americanheart.org/presenter.jhtml?identifier=2114, Carretero and Oparil
2000).  A thorough review of the current scientific and medical understanding of each of
the possible causes of hypertension is clearly beyond the scope of this Introduction.
However, a brief review of some of the proposed causes of hypertension will be presented.
Hypertension is diagnosed when the average of two or more diastolic blood pressure
(DBP= diastolic blood pressure; BP= blood pressure) measurements on at least two
subsequent occurrences is ≥90 mmHg or when the average of multiple systolic BP (SBP)
readings on two or more subsequent occurrences is consistently ≥140 mmHg and a BP of
≥140/90 mmHg is considered isolated systolic hypertension (Carretero and Oparil 2000).
According to the Sixth Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC VI), “hypertension” in adults can
be classified as borderline, Stage 1 (mild), Stage 2 (moderate) or Stage 3 (severe) while
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“isolated hypertension” is classified as either borderline or frank isolated hypertension
(JNC VI 1997, Carretero and Oparil 2000).  United States demographic data indicate that
hypertension is more prevalent in males, blacks, residents of the southeastern part of the
country and is inversely correlated to socioeconomic status (Carretero and Oparil 2000).
A detailed definition of “essential,” “primary,” or “idiopathic” hypertension is
necessary in order to facilitate a logical discussion of how NO production and
bioavailability relate to hypertension.  It may be useful to think of hypertension as a sequel
to other pathological conditions or a result of lifestyle choices rather than as a disease
completely unto itself.  This mindset becomes especially useful when searching the
literature for information about hypertension since the vast majority of articles discuss
hypertension as it presents in or accompanies preeclampsia, reno-vascular disease, renal
failure, aldosteronism and metabolic syndrome (which includes diabetes mellitus, obesity,
glucose intolerance, insulin resistance and dyslipidemia) (Carretero and Oparil 2000,
Hayashi 2001, Calhoun 2006, Yanai et al. 2008).  Essential hypertension, then, is high BP
in the absence of the secondary causes noted above and accounts for 95% of all cases
(Carretero and Oparil 2000).
Much work remains to be done to elucidate the pathogenesis (and especially the
genetic causes) of essential hypertension.  This work is extremely important since
modifiable lifestyle traits like excessive alcohol consumption, excessive salt intake, lack of
exercise, stress and low potassium and calcium intake can exacerbate what may only be a
mild, inherited, essential hypertension.  Definitively identifying the genetic causes of
hypertension is likely to be a long and painstaking process since both cardiac output and
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total peripheral resistance (TPR) regulate BP.  These factors are in turn regulated by other
factors such as autonomic responses, vasoactive hormones, body fluid volumes, renal
function and the structure of the cardiovascular system itself.  Finally, a greater
understanding of other non-modifiable risk factors, such as obesity, the aging process and
the metabolic syndrome may provide non-pharmacological targets for anti-hypertensive
therapies.
No fewer than ten genes have been demonstrated to increase or decrease BP by
increasing or decreasing salt and water reabsorption by the kidney (Carretero and Oparil
2000).  Several syndromes resulting from aberrations in this pathway have been identified
and include glucocorticoid-remediable aldosteronism, Liddle’s syndrome and apparent
mineralcorticoid excess.  Blood pressure is also sensitive to dietary salt intake and it is
thought that this sensitivity results from the combined effects of hyperinsulinemia,
hyperaldosteronism and increased sympathetic nervous system activity (Carrertero and
Oparil 2000).  Using Dahl salt-sensitive rats, Takenaka et al. demonstrated that salt-
sensitive hypertension reduces afferent arteriolar resistance and impairs the arteriolar
myogenic response, strongly suggesting that salt sensitivity determines renal microvascular
reactivity to pressure, as well as tubular sodium handling (Takenaka et al. 1992, Hayashi
2001).
Of the syndromes mentioned above, aldosteronism has been of particular interest to
hypertension researchers of late.  Conventional medical wisdom has, until now, held that
primary aldosteronism is an uncommon cause of hypertension.  This wisdom has been
challenged recently by data suggesting that perhaps as many as 15% of patients with
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essential hypertension and approximately 20% of patients with resistant hypertension
(defined as elevated BP despite the use of three anti-hypertensive agents) also meet the
biochemical criteria for primary aldosteronism (Calhoun 2006).  Furthermore, primary
aldosteronism is present in approximately 20% of individuals with resistant hypertension
(that is, hypertension that is refractory to standard anti-hypertensive therapies) (Calhoun
2006).  Cross-sectional studies by El-Gharbawy et al. and Grim et al. studying black
American and white French Canadian patients with hypertension demonstrated a
significant correlation between plasma aldosterone and 24-hour ambulatory blood pressure
levels.  The BP levels in both groups were unrelated to plasma renin activity, suggesting
that aldosterone has a greater contribution to worsening hypertension than renin-
angiotensin II (El-Gharbawy et al. 2001, Grim et al. 2005).  Aldosterone’s role in the
pathogensis of hypertension is further supported by work from Vasan et al. in which a
prospective analysis demonstrated that serum plasma aldosterone levels amongst
normotensive individuals participating in the Framingham Offspring Study were related to
subsequent increases in BP and the development of sustained hypertension, which is
defined as a BP measurement of >140/90 mmHg or the use of anti-hypertensive
medications (Vasan et al. 2004).  It should be noted, however, that renin activity was not
measured in the Vasan study, thus preventing a comparison of the predictive value of
aldosterone versus renin (Calhoun 2006).  Finally, the effectiveness of antihypertensive
mineralocorticoids such as spironolactone and eplerenone, which reduces BP even further
after administration of renin-angiotensin blockades in patients without primary
aldosteronism, suggests a broader role for aldosterone in hypertension (Calhoun 2006).
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Hypertension and the Metabolic Syndrome: Obesity, glucose intolerance,
dyslipidemia and hypertension are all hallmark characteristics of the metabolic syndrome
and it has been estimated that as many as one third of hypertensive patients also have the
metabolic syndrome (although not all patients with metabolic syndrome are hypertensive)
(World Health Organization 1999, Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults 2001, Cuspidi et al. 2004, Schillaci et al. 2004,
Guerro-Romero et al. 2005).  More specifically, visceral obesity is thought to play a
critical role in the development of hypertension via the deranged production and secretion
of bioactive substances, or adipocytokines, including leptin, tumor necrosis factor-α (TNF-
α), interleukin-6 (IL-6), angiotensinogen and non-esterified fatty acids (NEFA) (Yanai et
al. 2008).  These adipocytokines are also responsible for another key characteristic of the
metabolic syndrome, insulin resistance.
Insulin resistance causes sodium retention and potentiates both the production and
vasoconstrictive action of endothelin-1, which in turn leads to hypertension (Rocchini
2000, Sarafidis and Bakris 2007).  More relevant to the topic of nitric oxide’s relationship
to hypertension is the fact that insulin stimulates NO production.  In a state of insulin
resistance, endothelial NO production is attenuated and vascular tone consequently
increases.  Additionally, sodium retention has been shown to decrease renal medullary NO
production, which decreases the elevated renal blood flow typically associated with obesity
(Fujiwara et al. 1999, Hayashi 2001).  In 2005, Roberts et al. presented data collected from
rats with metabolic syndrome, demonstrating significant NO inactivation down-regulation
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of NOS (Roberts et al. 2005).  These results suggest oxidative stress and endothelial
dysfunction play a very strong role in the pathogenesis of hypertension in the metabolic
syndrome.  For the purposes of this chapter, “endothelial dysfunction” is a chronic
inflammatory disease referring to an “imbalance between relaxing and contracting factors”
in the vasculature, which can attenuate NO’s ability to cause vasodilation, although other
problems such as increased endothelial permeability and increased endothelial adhesion for
leukocytes are often associated with endothelial dysfunction (DeMeyer and Herman 1997,
Lum and Roebuck 2001, Cattaruzza et al. 2005, Buerk 2007).
In addition to the numerous factors already mentioned, the activated renin-
angiotensin system, or RAS, also regulates blood pressure by modulating both renal
function and vascular tone.  In 2003, Engeli et al. determined that food intake plays a
major role in regulating the RAS by increasing formation of angiotensin II in adipocytes
(Engeli et al. 2003).  Furthermore, angiotensin II inhibits the action of insulin through its
interaction with the angiotensin 1 receptor (AT1) and an increase in oxidative stress
(amongst other mechanisms) via mitogen-activated (MAP) kinases and NAD(P)H oxidases
(Fujita 2001).  The increased concentration of reactive oxygen species (ROS), which are
normally ubiquitous and short-lived, has numerous effects, including inhibition of
PI3K/Akt signaling, which decreases endothelial NO production and increases vascular
tone (Lum and Roebuck 2001, Sowers 2004).
ROS exert numerous other dose-dependent effects on their targets: in low
concentrations, ROS stimulate cytokine secretion and cell proliferation, while at high
concentrations they modify proteins by oxidation, peroxidize lipids and nick DNA strands.
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Just what becomes the target of a ROS is dependent on several factors including lipid
solubility, the cellular location of ROS generation and the half-life of the oxidant (Lum and
Roebuck 2001).  At this point it should be clear that ROS serve as important signaling
molecules at numerous points in numerous pathways.  The role of ROS as a signaling
molecule in the pathogenesis of hypertension will be discussed later in this chapter.
In 2001, Fujita published a brief review presenting several lines of evidence linking
an activated renin-angiotensin system to the pathogenesis of hypertension (Fujita 2001).  In
rats chronically infused with pressor and non-pressor doses of angiotensin II, both
endothelial dysfunction and hypertension developed as a result of increased vascular
superoxide anion production, which is thought to occur in the endothelium, media and
adventitia (Mollnau et al. 2002, Schulz et al. 2008).  Incubation of smooth muscle cells
with low-density lipoproteins (LDL) increases AT1 expression and mechanical stretch up-
regulates angiotensinogen, renin and angiotensin converting enzyme genes (Fujita 2001).
Perhaps most interestingly, the LDL receptor Cd36 has been implicated as a gene for
hypertension in spontaneously hypertensive rats (SHR) (Fujita 2001).  While Fujita’s
review elucidates some very important mechanisms related to the pathogenesis of
hypertension, many other potential mechanisms exist.
NO, Lipid Rafts and Redox Signaling: One of these mechanisms is redox
signaling by clusters of cholesterol- and sphingolipid-rich lipid rafts, or LRs, which are
situated in the cell membranes of many mammalian cells (Simons and Ikonen 1997,
Simons and Toomre 2000, Kabouridis 2006, Li et al. 2007).  Lipid rafts are defined by Li
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et al. as “dynamic assemblies of cholesterol and lipids with saturated acyl chains that
include sphingolipids and glycosphingolipids in the exoplasmic leaf of the membrane
bilayer” (Li et al. 2007).  Phospholipids with saturated fatty acids and cholesterol in the
inner leaflet are also important components (Li et al. 2007).  It has been proposed that the
long fatty acids of sphingolipids in the outer leaflet couple the inner and outer leaflets
together through interdigitation to form very stable, detergent-resistant membrane
structures which are able to either include or exclude proteins when cells respond to
physiological or pathological stimuli (Simons and Toomre 2000, Magee and Parmryd
2003, Li et al. 2007b).  While a complete and thorough review of LR formation and
function is outside the scope of this chapter, the role of LRs in endothelial
function/dysfunction and the pathogenesis of hypertension warrants further discussion.
Lipid rafts have recently been implicated as a signaling component of endothelial
cells, regulating several important endothelial functions including the endothelium-
dependent vasorelaxant or constrictor response (Patschan et al. 2006, Zhang et al. 2006, Li
et al. 2007b).  This signaling capability comes from LRs’ temporal-spatial organization
with caveolae, which allows LRs to use molecules such as vascular endothelial growth
factor (VEGF), hydrogen peroxide (H2O2) and NO to regulate endothelial function through
exertion of numerous effects, including the up- or down-regulation of NO production
(Pritchard et al. 2002, Yang et al. 2006, Li et al. 2007b). It is thought that large redox
signaling molecules aggregate in LR “clusters” which subsequently produce superoxide
and other ROS and contribute to the regulation of the endothelium-related vasomotor
response.  Data supporting this hypothesis have been collected in intact coronary arteries
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by Li et al. and the reader is referred to an excellent 2007 forum review by that group
which discusses the current scientific understanding of the function of lipid raft redox
signaling platforms in endothelial dysfunction (Li et al. 2007b).  There is now much
evidence to suggest that >95% of superoxide in the vasculature is produced by non-
mitochondrial NADPH oxidases (NOXs), with the balance coming from xanthine/xanthine
oxidase and uncoupled NOS (Mohazzab et al. 1994, Rajagopalan et al. 1996, Griendling et
al. 2000, Cai 2005, Li et al. 2007b).  Consequently, NOX is believed to play a critical role
in the normal regulation of endothelial function and development of several diseases,
including hypertension (Li et al. 2007b), and will be the focus of this chapter.
In order to discuss how NOS and NO are regulated by LRs, it is first necessary to
elaborate on the connection between caveolae and NOX.  Caveolae are small, flask-shaped
invaginations that can occupy up to 30% of the plasma membrane and can contain LRs
(Goligorsky et al. 2002).  Studies indicate that there is a correlation between caveolae
formation, NOS location/NO production and endocytosis in endothelial cells (Goligorsky
et al. 2002, Stan 2002, Li et al. 2007b).  This pairing of caveolae and NOS is important
because it allows for interaction between NOS and other signaling proteins including
caveolin-1, calmodulin and Akt, among others (Pritchard et al. 2002).  Caveolin-1, the
primary coat protein of caveolae in blood vessels, is associated with and inhibits NOS3
within caveolae under basal conditions by inhibiting the reductase domain function of the
enzyme (Bernatchez et al 2005).  It has been suggested that cortical F-actin also co-
localizes with NOS3 in the caveolae of pulmonary artery endothelial cells and that the
actin polymerization state and/or protein contents regulate NOS3 activity in a post-
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translational manner (Su et al. 2003).  However, NOS3 has also been detected in non-
caveolae LRs, which cluster in response to agonists or other stimuli to induce signaling
(Pritchard et al. 2002, Li et al. 2007a, Li et al. 2007b).  Such distribution suggests NOS and
other enzymes may mediate different pathways within the same cell, depending on the type
of stimulus present (Li et al. 2007b).  NOX has also been shown to be present in both
caveolae-associated (with caveolin-1) and non-caveolae-associated LRs.  Since angiotensin
II stimulates caveolae-associated NOX to produce superoxide, this is one potential
mechanism by which NO could be scavenged in and around the vasculature, leading to
endothelial dysfunction as NO reacts faster with superoxide and is present in high enough
concentrations so as to outcompete endogenous superoxide dismutase (Hilenski et al. 2004,
Ushio-Fukai and Alexander 2004, Zuo et al. 2005, Li et al. 2007b, Pacher et al 2007).
It is particularly telling that in their 2007 review, Li et al. state “the functional
significance of LR redox signaling platforms is still far from clear” (Li et al. 2007b).
However, the authors hypothesize that the formation of redox signaling platforms
contributes to endothelial dysfunction (associated with various death receptor agonists
such as FasL and TNF-α) which may lead to hypertension (among other diseases) (Li et al.
2007b).  Research has shown that endothelial cells have endogenous Fas ligand (FasL) on
their surface, making them resistant to FasL-induced apoptosis under normal physiological
conditions (Shakibaei et al. 2005, Li et al. 2007b).  If this endogenous pathway is disrupted
in some way, such as by the presence of an excess of FasL, endothelial dysfunction (versus
frank apoptosis) may result.  Unlike FasL, stimulation of endothelial cells with TNF-α
produces both pro- and anti-apoptotic cellular signals (Madge and Pober 2001, Shakibaei
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et al. 2005, Li et al. 2007b).  If enough TNF-α receptors are activated, apoptosis results,
although there is general agreement amongst experts in the field that there are certain
mechanisms in endothelial cells that protect them against apoptosis.  To this end, Lefer and
Ma as well as Zhang et al. have shown that TNF-α attenuates endothelium-dependent
vasorelaxation in a variety of vascular beds (Lefer and Ma 1993, Zhang et al. 2002, Li et
al. 2007b).  Finally, it has been suggested that endothelial dysfunction is actually a normal
precursor to apoptosis (Li et al. 2007b).
However, the question still remains: “What is the mechanism by which death
receptor activation causes endothelial dysfunction (as defined for the purpose of this
chapter)?”  Researchers have proposed several theories, including NOS3 inhibition (Zhang
et al. 1997, Makino et al. 2005, Li et al. 2007b), which will be discussed shortly, and a
decrease in the anti-oxidant enzyme superoxide dismutase (SOD), which catalyzes the
reaction: 2O2- + 2H+ → H2O2 (Whitsett et al. 1992, Lum and Roebuck 2001, Li et al.
2007b).  But it is the decrease in NO bioavailability due to the aggregation and
enhancement of NOX activity and superoxide production that is generally considered the
primary cause of impairment of endothelium-dependent vasorelaxation (Li and Shah 2001,
Lum and Roebuck 2001, Zhang et al. 2003, Li et al. 2007b).  Results from experiments
using coronary arteries suggest this NOX aggregation and up-regulation is a consequence
of ceramide-related LR clustering induced by FasL binding (Li et al. 2007b).  The excess
NOX-derived superoxide, produced in the vascular adventitia (which itself acts as a
functional barrier to NO), reacts with the endogenous NO at a rate three times faster than it
reacts with SOD, making the NO unavailable to exert its intended vasorelaxant effects
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(Thomson et al. 1995, Wang et al. 1998).  It is precisely because this reaction between NO
and superoxide is so fast that some experts hypothesize that superoxide is targeted by NO
is some vascular tissues in order to control endothelium-dependent vasorelaxation
(Griendling et al. 2000, Lassègue and Clempus 2003, Li et al. 2007b).
NOS “Uncoupling:” It was mentioned earlier that the interaction of NO and
superoxide produces peroxynitrite, a highly reactive free radical that can traverse cell
membranes through anion channels, which then breaks down to form two other potent
ROS: hydroxyl radical (•OH) and nitrogen dioxide (NO2•) (Beckman et al. 1990, Lum and
Roebuck 2001, Pacher et al. 2007).  Once formed, peroxynitrite oxidizes a critical cofactor
for NOS function, tetrahydrobiopterin (BH4), to dihydrobiopterin (BH2) (Vásquez-Vivar et
al. 1998, Zou et al. 2002, Li et al. 2007b).  This causes “NOS uncoupling” where electrons
normally flowing from the reductase domain of one subunit to the oxygenase domain of
the other subunit are diverted to molecular oxygen instead of L-arginine, causing the flavin
proteins present in the enzyme to directly reduce oxygen, thereby producing excess
superoxide instead of NO (Xia and Zweier 1997, Vásquez-Vivar et al. 1998, Zou et al.
2002, Schulz et al. 2008).
A decrease in BH4 bioavailability, thereby altering the stoichiometric relationship
between BH4 and NOS3, can also cause the enzyme to uncouple (Singh et al. 2007).
Disruption of either the de novo synthetic pathway (in which GTP is a precursor) or
salvage pathway, by which BH4 is produced, can also diminish BH4 bioavailability (Singh
et al. 2007).  In 2002, Zou and colleagues suggested that it was not the oxidation of BH4 to
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BH2 that causes NOS uncoupling but rather oxidation/disruption of the zinc-thiolate (ZnS4)
center or “cluster” formed by a zinc ion coordinated with pairs of cysteine residues at the
NOS dimer interface by peroxynitrite in a concentration-dependent manner, causing a
release of zinc which effects a structural change that cleaves NOS dimers into monomers
under reducing conditions and forms disulfide bonds between the monomers (Zou et al.
2002).  The group bases their conclusions on numerous pieces of experimental evidence.
They cite papers in which X-ray crystallography confirms the presence of the
aforementioned zinc-thiolate “cluster.”  Other studies have also demonstrated that
peroxynitrite reactions are greatly facilitated in the presence of metal-ion centers or heme-
thiolate “clusters”, such as those present in NOS enzymes. Next, the group determined
that the zinc-thiolate center in the NOS3 enzyme is disrupted at peroxynitrite
concentrations of 1 – 10 μM, which are 10- to 100-fold lower than concentrations required
to oxidize BH4 and that a 5,000-fold excess of BH4 over NOS3 did not prevent NOS3
dimer dissociation.  The interaction between peroxynitrite and the zinc-thiolate NOS center
appears to be highly selective because the addition of physiological concentrations of
glutathione (10 mM), physiological and high concentrations of L-arginine (0.5 mM and 1
mM, respectively) and BH4 (0.1 mM and 100 μM, respectively) and high concentrations of
exogenous reduced thiols did not prevent peroxynitrite-induced disruption of the centers.
Furthermore, zinc has the highest charge-to-atomic radius ratio of any element and will
attract anionic oxidants like peroxynitrite, which reacts with zinc-thiolate “clusters” 1000
times faster than with cysteine-thiols.  The paper goes on to report that high glucose
concentrations (30 mM) cause NOS3 dimers to dissociate into monomers by increasing the
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cellular content of 3-nitrotyrosine, which inactivates prostacyclin synthase through
tyrosine nitration, thereby attenuating vasorelaxation (Zou et al. 2002).  Finally, the
authors report that the zinc chelator NNNN-tetrakis (2-pyridylmethyl) ethylenediamine
(TPEN) mimicked the effects of peroxynitrite, suggesting it is indeed peroxynitrite and not
another molecule responsible for the experimental results they observed, and that H2O2
oxidizes free thiols without affecting NOS3 dimers or zinc content, suggesting that the
NOS zinc-thiolate center (versus free thiols) truly are the target of peroxynitrite.
Regardless of the cause, the excess superoxide produced from NOS uncoupling
contributes to oxidative stress within the cell and reduces the amount of NO available to
produce endothelium-dependent vasorelaxation (Katusic 2001, Tiefenbacher 2001, Zou et
al. 2002, Li et al. 2007b).  Support for the interaction between BH4 bioavailability, NO
bioavailability and ROS production comes from several clinical studies in which
administration of BH4 reduced endothelial dysfunction in patients with
hypercholesterolemia, coronary artery disease and a history of smoking (Stroes et al. 1997,
Heitzer et al. 2000, Maier et al. 2000, Thöny et al. 2000, Singh et al. 2007).  In 2007,
Heeba et al. demonstrated that 3-hydroxy-3-methylglutarylcoenzymeA (HMG-CoA)
reductase inhibitors (statins) can attenuate endothelial dysfunction in both normal and
highly dysfunctional human umbilical vein endothelial cells (HUVECs) by shifting the
NO/peroxynitritie balance in a favorable direction, suggesting that therapies currently used
for other conditions may someday play a role in directly combating endothelial
dysfunction (Heeba et al. 2007).
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NOS Downregulation: Nitric oxide bioavailability can also be attenuated by
down-regulation of the NOS enzyme itself.  This phenomenon has been particularly well-
studied in the NOS3 isoform, which is down-regulated by numerous factors including
TNF-α, hypoxia, endothelial proliferation, mixtures of interferon-γ and interleukin 1β in
the blood of individuals with microangiopathy, polymorphisms in the NOS3 haplotype,
oxidized low density lipoproteins, C-reactive protein [which activates NOX, causing ROS
generation and which blunts phosphorylation at Ser1179 in the reductase domain by
agonists such as VEGF, high density lipoproteins and insulin], hypertension and from the
endogenous NOS inhibitor asymmetric dimethyl-L-arginine (ADMA) in individuals with
hyperglycemia (Mantovani et al. 1992, Rosenkranz-Weiss et al. 1994, McQuillan et al.
1994, Flowers et al. 1995, Chou et al. 1998, Fard et al. 2000, Lin et al. 2002, Makino et al.
2005, Heeba et al. 2007, Singh et al. 2007).
In 2005, Makino et al. conducted a study investigating whether the negative effects
of TNF-α on NOS3 and apoptosis occur in the endothelial cells of patients with
microvascular complications (Makino et al. 2005).  Their methodology included
examining NOS3 protein expression and the presence of apoptosis in human umbilical
vein endothelial cells (HUVECs) after incubation with serum from Type 2 diabetic patients
both with and without microvascular complications.  The authors acknowledge that the
mechanism(s) underlying endothelial dysfunction in diabetic patients is/are not well
understood; however, they offered some possible explanations for their results.  They
discovered elevated levels of TNF-α and TNF-R1 (a TNF cell-surface receptor) in the
serum of patients with microangiopathy, leading the group to propose that high serum
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TNF-α level may partly contribute to endothelial dysfunction in diabetic patients via down-
regulated NOS3.  The authors also found elevated levels of ADMA in patients with
microangiopathy, but stopped short of implying that elevated ADMA levels activate TNF-
α.
The fascinating connection between NOS3 polymorphisms, NOS3 down-regulation
and endothelial dysfunction warrants further discussion.  In 2005, Cattaruzza et al.
demonstrated that a CC genotype of the 786C/T single-nucleotide polymorphism in the
NOS3 promoter region causes impaired shear stress sensitivity in NOS3 expressed in
patients with coronary disease and that this genotype is associated with a deficit in NOS3
expression in human endothelial cells upon exposure to laminar shear stress, with reduced
NO-mediated vasomotor function in freshly isolated human blood vessels and with a
significant increase in the presence of coronary heart disease in individuals under 65 years
of age undergoing quantitative coronary angiography (Cattaruzza et al. 2005).  These data
are important clinically because they suggest that reduced shear stress-dependent NOS3
activation may contribute to coronary heart disease (Cattarruzza et al. 2005, Landmesser
and Drexler 2005).  Prior to the 2005 study by Cattaruzza’s group, three NOS3 gene
polymorphisms were known to exist: 1) a 27 bp tandem repeat in intron 4 which may
affect basal NOS3 expression, 2) a G to T single nucleotide polymorphism at position 894
which results in an exchange of Glu 298 to Asp, which may alter protein stability, and 3) a
T to C transition at position -786 in the NOS3 promoter which is thought to be unlikely to
affect the function of the mature enzyme (Uwabo et al. 1998, Tesauro et al. 2000,
Cattaruzza et al. 2005).
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A study by Sandrim et al. in 2006 concluded that NOS3 haplotypes associated with
hypertension were independent of ethnicity (Sandrim et al. 2006).  That is to say,
statistically significant differences in haplotype were only found when comparing
hypertensive to normotensive subjects (Sandrim et al. 2006, Marson 2008).  It should also
be noted that the authors only studied individuals of black or white descent.  In contrast to
this finding, Srivastava et al. reported that Asian Indians carrying the Asp allele of the
Glu298Asp NOS3 gene polymorphism may be at higher risk for essential hypertension
(Marson 2008, Srivastava et al. 2008).  Given this apparent discrepancy it is clear that
much work remains to be done to determine what role NOS3 gene markers may have in
predicting the susceptibility of different populations to hypertension (Marson 2008).
Specific Roles of sGC and cGMP: The roles that sGC and cGMP play in the
complex NO/hypertension relationship warrant further discussion.  In 1996, Rajagopalan
and colleagues found that hypertensive rats demonstrated decreased responsiveness to the
endothelium-independent nitro-vasodilators sodium nitroprusside and nitroglycerin as well
as endothelium-dependent vasodilators (Rajagopalan et al. 1996, Schulz et al. 2008).  In a
2008 review, Schulz et al. attributed this finding, in part, to decreases in 1) expression of
one or both subunits (α1 and β1) of sGC and 2) NO-dependent sGC activity which has been
observed in both genetic and drug-induced hypertensive animal models (Ruetten et al.
1999, Jacke et al. 2000, Klöss et al. 2000, López-Farré et al. 2002, Witte et al. 2002,
Schulz et al. 2008).  A decrease in blood pressure normalized or enhanced sGC expression,
but had differing effects on vascular superoxide production, suggesting that the decrease in
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sGC expression seen in hypertension is not exclusively linked to increased superoxide
formation and/or increased levels of vasoconstrictor peptides (Schulz et al. 2008).
Interestingly, Schulz et al. go on to report that angiotensin II and endothelin-1, both of
which are up-regulated in hypertension, seem to cause an up-regulation of sGC in VSMCs.
However, this up-regulation seems to be “overwhelmed” by as yet unknown mediators of
hypertension, which then cause a decrease in sGC expression (and therefore NO/cGMP
signaling), leading to endothelial and smooth muscle dysfunction (Schulz et al. 2008).
Finally, there is some in vitro evidence that increased cGMP metabolism may
contribute to endothelial dysfunction.  In 2001, Kim et al. found that angiotensin II
increased both the expression and activity of the cGMP-specific phosphodiesterase 1A1 in
cultured smooth muscle cells, suggesting that increased cGMP metabolism may promote
endothelial dysfunction in angiotensin II-induced hypertension (Kim et al. 2001, Schulz et
al. 2008).
Capillarity and Rarefaction in Skeletal Muscle Tissue: In an excellent 2006
review of hypertension as a disease of the microcirculation, Feihl et al. define capillaries as
“vessels ranging from 4 to 12 µm in diameter in which the walls are composed exclusively
of endothelial cells more or less fenestrated according to the organ and a basement
membrane” (Feihl et al. 2006).  The endothelial cells are rolled up into tubes that comprise
one segment of the capillary.  Their function is to ensure fluid-metabolite exchange
between plasma and tissues which requires high wall permeability.  However, a
consequence of this high permeability is fragility of the vessel.  While normal systemic
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capillary pressure is a relatively low 10 – 30 mmHg, distal capillaries can be damaged by
local hypertension.  Myogenic tone, an intrinsic property of vascular smooth muscle which
causes it to contract when stretched, protects these fragile capillaries by amplifying
arteriolar resistance to flow (Feihl et al. 2006).
The pattern of the capillary network in skeletal muscle has been the subject of
study for well over 100 years.  In 1919, August Krogh presented the first model of
capillary anatomy in skeletal muscle, consisting of a parallel arrangement of vessels
embedded in a skeletal muscle fiber matrix (Krogh 1919, Skalak and Schmid-Schönbein
1986).  However, the model was considered too simplistic to form the foundation for
quantitative predictions of transport in skeletal muscle as it ignores capillary network
arrangement and fails to describe how arterioles and venules connect with the capillary
network (Skalak and Schmid-Schönbein 1986).  Therefore, in 1986, Skalak and Schmid-
Schönbein set out to propose a new network model for skeletal muscle capillaries.
Interestingly, their work was carried out in the spinotrapezius muscle of 16-20 week old
male WKY and SHR rats (Skalak and Schmid-Schönbein 1986).  They discovered that
capillaries are interconnected across a limited number of fibers, creating “capillary
bundles” which are in turn connected by transverse arterioles or collecting venules which
may interconnect with several bundles.  The arterioles and venules branch out in an
alternating sequence, creating a “capillary bundle element” which consists of the segment
from a transverse arteriole to its neighboring collecting venule (Skalak and Schmid-
Schönbein 1986).  It is important to note that this arrangement allows for control of
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capillary pressure in the presence of large flow fluctuations by the vasoactive transverse
arterioles by purely anatomical means.
Another interesting finding of the Skalak and Schmid-Schönbein study was that in
the SHR the capillary network exhibits relatively straight arteriovenous pathways with a
reduced density of the meshwork.  However, they failed to find any indication of a reduced
number of parallel pathways per bundle element (Skalak and Schmid-Schönbein 1986).
The importance of this finding will be discussed shortly, but first it is important to present
what is known about capillary density and the arrangement of vessels in mammalian
species.
In a comprehensive 1975 study, Plyley and Groom studied the geometrical
distribution of capillaries in dog, cat, rabbit, rat and guinea pig striated muscle and set out
to answer the question “how many vessels are needed around the circumference of a
muscle fiber in order to satisfy its O2 requirements?” (Plyley and Groom 1975).  They
counted capillaries in tissue sections from each species and calculated number of
capillaries around a fiber, mean capillary:fiber ratio and the mean number of capillaries
and fibers per square millimeter.  Several conclusions regarding capillary number and
density were drawn from these data.  One conclusion is that although capillary density
varied between species, the frequency distribution for capillaries around a fiber was nearly
the same in all species studied, suggesting that any differences in capillary density are
primarily a consequence of differences in mean fiber size.  Another conclusion supports
the notion that differences in mean fiber size indicate differences in metabolic rate and rate
of O2 supply.  Thirdly, the authors suggest that nature prefers to increase O2 supply by
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decreasing the diameter of a muscle fiber rather than by increasing the number of
capillaries around the perimeter of the fiber.  When the arrangement of vessels and fibers
in transverse sections of red (oxidative) and white (glycolytic) fibers were compared, the
authors were surprised to see there were no significant differences in the mean number of
vessels around a fiber and were unable to conclusively explain the reasons for the
discrepancy, suggesting the literature, with reports both confirming the refuting the present
findings, is far from clear regarding capillary density in red versus white muscle fibers
(Plyley and Groom 1975).  Sullivan and Pittman also failed to detect a significant
difference in the number of capillaries surrounding oxidative and glycolytic fibers in
hamster striated muscle tissue (Sullivan and Pittman 1983).
Although there are still unanswered questions about capillary density in different
fiber types, a report in 1991 by Bennett et al. suggests that capillaries are preferentially
located in the vertices of striated muscle tissue (Bennett et al. 1991).  The authors offered
two explanations for this finding.  First, perhaps there may be more room for capillaries to
grow in the vertex region than between muscle fibers.  Second, this observation may be a
result of efficient ordering of the capillaries and muscle fibers (Bennett et al. 1991).  In line
with the observations mentioned above, Bennett et al. also noted that the average shape of
male golden skeletal hamster fibers is much closer to hexagonal than square (Bennett et al.
1991).  These shape data are especially important when modeling transport and
consumption of molecular oxygen and NO.  Indeed, many investigators interested in such
modeling normally collect “traditional” descriptors of capillarity, including capillary
density, capillary:fiber ratio and number of capillaries around a fiber (Bennett et al. 1991).
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However, a better assessment offered by Sullivan and Pittman (1987) is the percent of
muscle fiber perimeter in contact with the capillary membrane (i.e. capillary-fiber contact)
(Sullivan and Pittman 1983, Bennett et al. 1991).  Interestingly, if this assessment is used,
Sullivan and Pittman detected a significantly higher percent capillary-fiber contact in
oxidative versus glycolytic fibers in hamster skeletal muscle tissue (Sullivan and Pittman
1983).
Another debate in the (primarily) hypertension literature is whether or not
rarefaction of the microvasculature is a real phenomenon and, if so, to what degree does it
occur.  Rarefaction is defined as “a reduced spatial density of microvascular networks”
(Feihl et al. 2006).  However, rarefaction can be functional, structural or both.  Feihl et al.
define functional rarefaction as “an abnormal prevalence of anatomically existing but
unperfused microvessels,” whereas structural rarefaction “can be established either by
quantitative histology or by the observation of microvascular beds in vivo under conditions
maximal vasodilation and optimal perfusion pressure” (Feihl et al. 2006).  Chen et al.
(1981) reported structural rarefaction in 4-week old SHRs and a 1982 report by the same
group in SHRs ranging in age from 6 to 18 weeks of age demonstrated similar results
(Prewitt et al. 1982).  Furthermore, Green et al. (1990) observed an approximately 14%
reduction in capillary density in SHRs compared to age-matched controls.  Although
Skalak and Schmid-Schönbein (1986) did not observe evidence of rarefaction, they did
note that there were fewer anastomotic connections in the capillary network of SHRs
compared to the WKY subjects, suggesting a less tortuous path of flow in capillaries of
the SHR than in those of the WKY (Skalak and Schmid-Schönbein 1986).
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Although the cause(2) of rarefaction remain(2) elusive, a recent study using 12- to
14-week old SHR rats with established diminished functional capillary density in their skin
and skeletal muscles compared to their age-matched controls, provided evidence that anti-
hypertensive drugs have “distinct capacities for reducing or reversing functional and/or
structural microvascular alterations in arterial hypertension…” (Sabino et al. 2008).
Given that NOS3 was first demonstrated in endothelial cells, the role of NO in
rarefaction has been the subject of study as well.  It has been suggested that NO plays a
key role in appropriate vascular budding in wound healing and stimulates the expression of
vascular growth factors, including vascular endothelial growth factor (VEGF) (Lee et al.
1999, Feihl et al. 2006).  Furthermore, impaired angiogenesis has been directly
demonstrated in experimental hypertension induced by chronic pharmacological inhibition
of NO synthesis (Kiefer et al. 2002, Feihl et al. 2006).  These findings further illustrate the
ongoing need for an accurate technique to measure NO in vivo to further explore the
crucial connection between NO and angiogenesis.  Future studies in this area will
hopefully shine some light on this puzzling phenomenon.
Fiber Type Nomenclature: Although a thorough review of the development of
the immunohistochemical fiber typing techniques used in this project are beyond the scope
of this Introduction, a few words about the fiber type nomenclature used in the study are
warranted and the reader is referred to an excellent review of this topic by Pette and Staron
(1990).  Pioneering work by Barnard et al. (1971) and Peter et al. (1972) lead to the
development of a fiber type nomenclature based on a combination of metabolic enzyme-
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based and mATPase-based histochemical study.  This combination technique lead to the
isolation of three major fiber types in guinea pig and rabbit:  slow-twitch oxidative (SO),
fast-twitch oxidative glycolytic (FOG) and fast-twitch glycolytic (FG) (Barnard et al. 1971,
Peter et al. 1972, Pette and Staron 1990).  In the late 1960s it was discovered that fast and
slow myosins have different alkaline and acid stabilities (Sréter et al. 1966, Seidel 1967,
Pette and Staron 1990).  These observations lead to more refined methods for mATPase-
based fiber delineation as fast fibers display high mATPase activity under alkaline
conditions and low activity under acid conditions whereas slow fibers exhibit the inverse
(Pette and Staron 1990).
Further study indicated that distinction into only two fiber types was an
oversimplification and led to delineation of fast fiber sub-types based on the intensity of
staining after pre-incubation at varying pH:  IIA, IIB and IIC.  An additional myosin heavy
chain protein, IId, was discovered by Pette and colleagues and the fibers containing this
isoform were designated IID (Note:  lower case letters designate the protein while upper
case letters designate the fiber type in which the protein is expressed) (Bär and Pette 1988,
Termin et al. 1989, Hämäläin and Pette 1993, Delp and Duan 1996).  However, the Type
IID fiber was found to be synonymous with the Type IIX fiber identified by Schiaffino and
colleagues and is now, therefore, referred to as Type IID/X (Schiaffino et al. 1985 and
1988, LaFramboise et al. 1990, Delp and Duan 1996).  Importantly, Pette and Staron
(1990) also reported that muscle fibers are capable of transforming from one fiber type
extreme to the other (see Discussion for further details) while Bortolotto et al. (1999)
reports that these hybrid fibers, as they are referred to while in transition, cannot be
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reliably detected by either enzyme-based histochemistry or immunohistochemistry
(Bortolotto et al. 1999)
Details regarding the compatibility of different histochemical classification
schemes are beyond the scope of this Introduction so the reader is once again referred to
Pette and Staron’s 1990 review and Delp and Duan’s comprehensive 1996 study
examining the fiber composition of rat skeletal muscle (Pette and Staron 1990).  However,
it is clear from a review of the literature that data gathered using the fiber-typing results
outline above must be interpreted with great care, especially when attempting to generalize
results from one species to another or even one muscle or muscle group to another within
the same species.
Goals of the Project and Conclusion: At this point it should be clear to the reader
that the relationship between NO production/bioavailability and hypertension is extremely
complex.  Obviously, much work remains to be done in the fields of nitric oxide and
hypertension research.  Hopefully this Introduction has elucidated some important aspects
of NO’s role in mammaliam physiology and in some of the proposed pathogenic
mechanisms of hypertension.  Many of the mechanisms and molecular/biochemical
pathways discussed here could potentially become novel anti-hypertensive therapy targets
in the future and the future research produced by the groups mentioned in this Introduction
should prove to be most interesting.  In any case, there is little doubt that as long as
humans continue to suffer from this devastating condition, the search for a cure will
continue.
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The overall goal of this project is to determine if there is a significant difference in
the expression of the three NOS isoforms in SHR and WKY postural skeletal muscle
(spinotrapezius) tissue.  There are four hypotheses driving the current study:  1) NOS1 will
be co-localized with Type I skeletal muscle fibers in both WKY and SHR rats, 2) NOS2
will be co-localized with Type II skeletal muscle fibers, 3) NOS3 will be located primarily,
if not exclusively, in endothelial tissue and 4) NOS concentrations in the spinotrapezius
muscle of SHR will be greater than the concentrations of the NOS isoforms in the
spinotrapezius muscle of WKY rats.  In addition to exploring the hypotheses mentioned
above, morpho- and geometric data will be collected about Type I, IIA and IIB muscle
fibers in each strain, expression of Type I, IIa and IIb MHC protein will be determined by
gel electrophoresis and capillarity data from both strains will be collected via alkaline
phosphatase staining for capillary endothelium.
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MATERIALS AND METHODS
Experimental Animal Preparation: Nine Wistar-Kyoto (WKY) rats and nine
spontaneously hypertensive rats (SHR) aged approximately 16.5 weeks (young adult with
hypertension fully manifested in SHR subjects) were used in this study (Harlan,
Indianapolis, IN). The rats were initially anesthetized with a ketamine/acepromazine
mixture, i.p. (75 mg/kg and 2.5 mg/kg, respectively) and the spinotrapezius muscle was
prepared, with minor modifications, according to the procedure described by Gray (1973).
Other steps in the preparation, including cannulations and blood sampling, were carried out
following the standard procedures used in our laboratory for several years. The muscle
was kept moist with warm physiological saline during dissection.  Mean arterial blood
pressure was monitored via a cannula in the carotid artery. Supplemental anesthetic
(Alfaxan 10 mg/ml; 0.02 ml/kg/minute; Vetoquinol UK Limited, Vetoquinol House, Great
Slade, Buckingham Industrial Park, Buckingham, UK) was continuously infused via a
cannula in the jugular vein.  Animal and muscle temperatures were maintained at 37 oC by
separate heat exchangers within the Lexan animal platform. Following collection of
spinotrapezius muscle tissue, animals were euthanized with Euthasol (0.4 mg/kg i.v.;
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pentobarbital 390 mg/ml and phenytoin 50 mg/ml; Delmarva, Midlothian, VA).  All
procedures were approved by the Institutional Animal Care and Use Committee of
Virginia Commonwealth University.
Immunohistochemical Protocol for Detection of Nitric Oxide Synthase in Skeletal
Muscle Tissue: The spinotrapezius muscles were exteriorized bilaterally, using the
methods and techniques outlined in the preceding section.  Care was taken to keep the
muscles moist with frequent application of phosphate-buffered saline (PBS) until they
were fully dissected away from underlying tissues and removed.  The two spinotrapezius
muscles, each approximately 500 µm thick, were placed one on top of the other (for ease
of sectioning) and folded along the long axis of the muscles.  The muscle tissue was then
be pinned to a small section of dental wax, placed in a small foil container and submerged
in a gel tissue freezing medium (TBSTM, Triangle Biomedical Sciences, Durham, NC) for
cryoprotection during freezing in liquid nitrogen-chilled isopentane (Thermo Fisher
Scientific Inc, Waltham, MA).  The frozen tissue was then cut into 10 μm thick cross
sections on a cryostat (Thermo Fisher Scientific Inc, Waltham, MA) and affixed to glass
slides (75 x 25 mm; Thermo Fisher Scientific Inc, Waltham, MA).  A brightfield
microscopy staining protocol, based on a protocol provided by the laboratory of Dr. Mary
Shall of the Department of Physical Therapy and modified from Segal et al. 1999, was
utilized during the preparation of the sectioned specimens for immunohistochemical
analysis.  The sections were fixed for 15 minutes in 2% paraformaldehyde-phosphate
buffer solution (PFA-PBS:  PBS from Sigma-Aldrich, St. Louis, MO; PFA from Electron
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Microscopy Sciences, Hatfiled, PA) chilled to 4 °C.  After rinsing with room temperature
(RT) 0.05 M Tris saline (TSS; Tris from BioRad Laboratories, Hercules, CA) six times
quickly, the sections were permeabilized for 20 minutes at RT in 0.1% Triton X-100/0.05
M TSS (VWR International, Radnor, PA).  After rinsing six times quickly with RT 0.05 M
TSS, endogenous peroxidase activity was quenched by incubation in RT 3% hydrogen
peroxide diluted in 40% 0.05 M TSS-60% methanol (Thermo Fisher Scientific Inc,
Waltham, MA).  After rinsing six times quickly with RT 0.05 M TSS, the sections were
blocked for four (4) hours at RT in normal goat serum from the Vectastain Avidin:
Biotinylated enzyme Complex (ABC) Peroxidase Elite Series kit (Vector Laboratories,
Burlingame, CA).  After pouring off the blocking solution, the sections were incubated at 4
°C overnight with the primary, rabbit, polyclonal antibody corresponding to the NOS
isoform of interest.  Primary NOS antibody dilutions were as follows: anti-NOS 1=1:2000
(Millipore, Temecula, CA), anti-NOS2=1:500 (Enzo Life Sciences, Plymouth Meeting,
PA) and anti-NOS3=1:50 (Santa Cruz Biotechnology, Santa Cruz, CA).  All primary
antibody solutions contained 2% bovine serum albumin (BSA)-0.1 M TSS (BSA:  Thermo
Fisher Scientific Inc, Waltham, MA).  After washing off the anti-NOS primary antibody
three times for five minutes each with RT 0.05 M TSS, the sections were first incubated in
anti-rabbit IgG biotinylated secondary antibodies (Vector Laboratories, Burlingame, CA)
for 30 minutes at RT and then in Vector Laboratories’ (Burlingame, CA) proprietary
avidin-biotinylated enzyme complex reagent for 60 minutes at RT.  Slides were then rinsed
three times for five minutes each with 0.05 M TSS and then incubated in nickel-free 3,3-
diaminobenzidine (DAB; Vector Laboratories, Burlingame, CA) for approximately 45-60
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seconds and then rinsed in distilled water for five minutes.  Slides were then carefully
dried to remove excess moisture and CC/Mount Aqueous Mounting Medium™ (Sigma-
Aldrich, St. Louis, MO) was applied.  Sections were covered with a No. 1 coverslip (VWR
International, Radnor, PA), slides sealed with clear nail polish and then stored at RT until
ready for viewing.
Immunohistochemical Typing of Skeletal Muscle Fibers: Bilateral spinotrapezius
muscles were exteriorized, frozen and sectioned as noted in the preceding section. A
muscle fiber typing microscopy staining protocol, provided by the laboratory of Dr. Mary
Shall of the Department of Physical Therapy, was utilized during the preparation of the
sectioned specimens for immunohistochemical analysis.  The sections were blocked in
normal horse serum (for fast, slow and Type IIA fibers; Vector Laboratories, Burlingame,
CA) or normal goat serum (for Type IIB fibers; Vector Laboratories, Burlingame, CA) for
20 minutes at room temperature.  After pouring off the blocking solutions, the sections
were incubated with the primary myosin heavy chain (MHC) antibody, corresponding to
the fiber type of interest, for one hour at RT at the following dilutions: fast at 1:20 (Vector
Laboratories, Burlingame, CA), slow at 1:50 (Vector Laboratories, Burlingame, CA), Type
IIA at 1:50 (DSHB, Iowa City IA) and Type IIB at 1:50 (American Type Culture
Collection, Manassas, VA).  The MHC, fast, IIA antibody 2F7 developed by Christine
Lucas (Department of Physiology, University of Sydney, Sydney, Australia) was obtained
from the Developmental Studies Hybridoma Bank developed under the auspices of the
NICHD and maintained by the University of Iowa, Department of Biology, Iowa City, IA
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52242.  After rinsing the primary MHC antibodies off the slides with phosphate-buffered
saline (PBS) for 10 minutes, the sections were incubated with either Vectastain Anti-
Mouse IgG (for fast and slow fibers), biotinylated anti-mouse rat-absorbed IgG (for Type
IIA fibers) or biotinylated anti-mouse IgM (for Type IIB fibers) for 30 minutes at RT.  All
secondary antibodies were from Vector Laboratories, Burlingame, CA.  Secondary
antibodies were rinsed from sections with PBS for five minutes and sections then
incubated in Vectastain Avidin: Biotinylated enzyme Complex (ABC; Vector
Laboratories, Burlingame, CA) for 30 minutes at RT.  Slides were then rinsed with PBS,
incubated in 3,3-diaminobenzidine (DAB; Vector Laboratories, Burlingame, CA) for
approximately 60-90 seconds and then rinsed in deionized water.  Slides were then
dehydrated through serial alcohols (10 dips in 95% ethanol 2 times; 60 seconds in absolute
ethanol 2 times) and xylenes (alcohols and xylenes from Thermo Fisher Scientific,
Waltham, MA), coverslipped with Permount Mounting Medium (Thermo Fisher Scientific,
Waltham, MA), sealed with clear nail polish and stored at RT until ready for viewing.
Immunohistochemical Staining for Endothelial Cells in Skeletal Muscle Tissue using
Alkaline Phosphatase Protocol: Bilateral spinotrapezius muscles were exteriorized,
frozen and sectioned as described in the preceding sections. An alkaline phosphatase
staining protocol for frozen sections was obtained from the website
http://www.ihcworld.com/_protocols/special_stains/alkaline phosphatase.htm and
modified for use in the laboratory to prepare sectioned specimens for
immunohistochemical analysis of co-localization of endothelial cells and endothelial NOS
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(NOS 3).  Sections were fixed in ice-cold acetone (Thermo Fisher Scientific, Waltham,
MA) for five minutes and then allowed to air dry for five minutes.  Slides were then placed
in the substrate working solution, consisting of a napthol AS-MX phosphate/N, N
dimethylformamide (DMF) solution (napthol phosphate from Sigma-Aldrich, St. Louis,
MO; DMF from Thermo Fisher Scientific, Waltham, MA), Tris-HCl buffer at pH 8.74
(Tris from BioRad Laboratories, Hercules, CA) and deionized water for approximately 60
minutes at 37 °C.  Slides were then rinsed in deionized water (3 times, 2 min per rinse),
carefully dried to remove excess moisture and CC/Mount Aqueous Mounting Medium™
(Sigma-Aldrich, St. Louis, MO) was applied.  Sections were covered with a No. 1
coverslip (VWR International, Radnor, PA) and slides sealed with clear nail polish and
stored at RT until ready for viewing.
Microscopic Analysis of Immunohistochemical Staining
General Procedures and Procedures for NOS 1/2 Image Acquisition: All NOS images,
with the exception of the NOS1 practice images used to determine NOS1 / Slow MHC
fiber co-localization, were acquired with an Olympus microscope (Model BH-2, Olympus
Optical Company, Ltd., Tokyo, Japan) using the ImagePro v7.0.0.591 software package
(Media Cybernetics, Inc., Bethesda, MD).  The scale factor was determined by measuring a
known distance on a stage micrometer slide.  The specimen was brought into focus at 20X
and Köhler illumination was established.  An area of interest (AOI) was then selected
based on the following inclusion criteria:  1) fibers were undamaged by any one of the
three aforementioned staining protocols; 2) no mounting medium artifact or air bubbles
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were present; 3) fibers were a sufficient distance (at least 50 µm) from the edge of the
specimen; and 4) there was no chromogen (DAB) artifact.  Automatic software algorithms
were used to calculate an exposure time of ~100 ms (± 10 ms) and to white balance the
image prior to acquisition.  All images, regardless of final image format, were processed
using the Sharpen and HiGauss filters included in the ImagePro software package.
Grading of NOS1 Images: Serial sectioning and staining were used to locate NOS1
fibers that co-localized with Type I fibers.  After screening images for qualitative
differences in degree of staining, a total of 17 images were selected for grading by seven
independent observers to quantify the degree of NOS co-localization.  To ensure as much
objectivity of scoring as possible, all grading was performed on the same PC/monitor setup
under identical lighting conditions.  Before grading began, the observers were issued an
instruction sheet (Appendix A).  After giving the observers time to read the instructions
and answering any procedural clarification questions, the observers graded three “practice”
images, all from WKY control animals, using the 0 to 3 scale described in Appendix A.
No feedback regarding scoring was provided before observers began grading experimental
images, which were obtained from both control (WKY) and experimental (SHR) animals.
Examination of NOS2 Images: Serial sectioning and staining were used to locate NOS2
fibers that co-localized with Type IIA/B fibers in both control (WKY) and experimental
(SHR) animals.  However, screening images for qualitative differences in degree of
staining failed to detect appreciable differences requiring independent observer grading.
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MHC Skeletal Muscle Fiber-typing Acquisition Protocol: Whenever possible, fibers
from two separate regions of each muscle section were used for data collection. Type I,
Fast (Type IIA/B), Type IIA and Type IIB fibers (“positive” fibers), as well as unstained
(“negative”) fibers within the AOI, were counted and seven metrics collected by outlining
the fiber using ImagePro’s tracing function.  These metrics included:  cross-sectional area
(A; in µm2), perimeter (P; in µm), maximum diameter (in µm), minimum diameter (in
µm), maximum radius (in µm) and minimum radius (in µm).  Since, visually, the muscle
fibers exhibited an approximately elliptical shape, area and perimeter data were used to
determine the major and minor diameters of an equivalent ellipse with the same cross-
sectional area and perimeter.  The major diameter of the equivalent ellipse (D; in µm) was
determined using the following formula:
D = [(P / π) • {1 + √[1 – (4πA/P2)]2}]1/2
Likewise, minor diameter of the equivalent ellipse (d; in µm) was determined using the
formula:
d = 4A/π • D
Finally, as an index of the eccentricity () of the ellipse, the minor diameter/major diameter
ratio was determined using the formula:
 = d/D
Fibers intersecting the upper transverse and left longitudinal lines of the AOI, as well as
fibers that could not be entirely visualized, were excluded from counting.
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NOS 3 Image Acquisition Protocol: All NOS3 images were collected according to the
NOS1/2 image acquisition protocol outlined above.  However, after capture, the color
image was converted to an 8-bit grayscale image (grayscale 8) for ease of storage and
transfer to other image-viewing platforms.  Images were then processed using the Sharpen
and HiGauss filters included in the ImagePro software package.
Examination of NOS3 Images: Images from WKY and SHR strains were scrutinized for
qualitative differences in degree of staining in several structures, including arterioles,
capillaries and venules.
Image Acquisition Protocol for Endothelial Cells in Skeletal Muscle Tissue
Capillaries via Alkaline Phosphatase staining: After acquiring a fiber-typing image
using the general procedures above, the image was converted to grayscale 8 for ease of
storage, manipulation and analysis between image software platforms.
Capillary Counting Protocol: Image analysis began with the establishment of an AOI
that includes as much tissue as possible without inclusion of gaps that were created when
the samples were “bulked up” before sectioning as outlined in “Immunohistochemical
Protocol for detection of Nitric Oxide Synthase in Skeletal Muscle Tissue” section.  Total
cross-sectional area of the AOI was recorded and total number of capillaries within the
AOI was determined by manual counting, with care taken not to “double count” capillaries
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that were in close proximity to one another.  Capillary density was then determined by the
formula:
Capillary density = number of capillaries in AOI/Cross-sectional area of AOI
To determine the average number of capillaries around a fiber, several fibers within the
AOI and with clearly associated capillaries were selected.  The fibers had to be entirely
visible in order to be counted.  These associated capillaries were counted and used to
determine the number of capillaries around a fiber (CAF).
Western Blot Analysis of NOS Isoforms in Skeletal Muscle Tissue:
Two Western blots were performed.  In the first blot, exposure times were corrected so that
valid comparisons could be made between the NOS isoforms being studied.  In the second
blot, all membranes were simultaneously probed for both the NOS isoform of interest, as
well as α-tubulin.
Tissue Preparation: Bilateral spinotrapezius muscles were exteriorized, blotted (taking
care to remove all blood and connective tissue), weighed, snap-frozen in liquid nitrogen-
chilled isopentane (Thermo Fisher Scientific Inc, Waltham, MA) and stored at -80 °C until
ready for processing.  Samples were then ground using a mortar and pestle that had been
chilled with liquid nitrogen.  Fresh lysis buffer was then prepared and consisted of 50 mM
Tris-HCl, 5 mM EDTA, 10 mM EGTA, 50 µg/mL protease inhibitor (Thermo Fisher
Scientific Inc, Waltham, MA) and 0.3% 2-mercaptoethanol.  Lysis buffer was added to
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ground tissue samples and first homogenized at 30 rpm for 10 repetitions and then
sonicated for 20 seconds, three times per sample.  Homogenized samples were placed on
ice for 30 minutes and then centrifuged at 12,000 g for 10 minutes a 4 °C.
Total Protein Concentration Determination via the Bradford Method: Two µL of
sample were mixed with 798 µL of deionized water and 200 µL Bradford reagent (BioRad
Laboratories, Hercules, CA), shaken to mix and then vortexed before being transferred into
spectrophotometer cuvettes.  The spectrophotometer dilution setting was set to 500, optical
density readings were made at 598 nm and then the samples were discarded.
Gel Electrophoresis Protocol: The sample buffer containing 50 µL betamercaptoethanol
and 950 µL Laemmli buffer was added to homogenized tissue samples and vortexed,
boiled for five to seven minutes and briefly centrifuged. 4-20% Criterion TGX Precast Gel
(BioRad Laboratories, Hercules CA) was then loaded and sample buffer containing Tris,
glycine and SDS was added.  Samples were loaded and run at 190 V until the samples
progressed through the stacking gel. Voltage was then reduced to 165 V and run for an
additional 90 minutes.
Nitrocellulose Transfer Protocol: Finished gel was placed between layers of fibrous
padding, filter paper and nitrocellulose (BioRad Laboratories, Hercules, CA), gently rolled
to remove bubbles, placed in chilled transfer buffer and run at 300 mA and 40-60 V for 90
minutes.
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Probing of Membrane: After verifying success of transfer with Ponceau stain (Sigma-
Aldrich, Sigma-Aldrich, St. Louis, MO), the membrane was washed with Tris-buffered
saline/Tween-20 (TBST) [100 mL TBS (Sigma-Aldrich, Sigma-Aldrich, St. Louis, MO),
900 mL deionized water, 500 µL Tween-20 (Sigma-Aldrich, Sigma-Aldrich, St. Louis,
MO)] then blocked with 5% milk in TBST (5 g milk in 100 mL TBST; Tween-20 (Sigma-
Aldrich, Sigma-Aldrich, St. Louis, MO) for at least one hour.  Separate primary antibody
solutions for NOS1-3, phosphorylated NOS1 and NOS3 and α-tubulin were prepared by
adding 10 µL of antibody to 5% milk/TBST.  The membrane was incubated in a cold room
overnight with a single primary antibody in the following order:  NOS1, NOS2, NOS3,
phosphorylated NOS1 (first blot only), phosphorylated NOS3 (first blot only) and α-
tubulin (NOS 1 antibody: Millipore, Temecula, CA; NOS2 antibody: Enzo Life Sciences,
Plymouth Meeting, PA; NOS3 antibody: Santa Cruz Biotechnology, Santa Cruz, CA;
phosphorylated NOS1 antibody:  Millipore, Temecula, CA ; phosphorylated NOS3
antibody and α-tubulin antibodies:  Cell Signaling Technology, Danvers, MA).  After
incubation the membrane was washed 4 – 5 times with TBST.  The membrane was then
incubated for at least one hour (and not more than three hours) in secondary antibody
solution consisting of 3.5 µL donkey anti-rabbit IgG HRP-linked whole secondary
antibody (GE Healthcare, Waukesha, WI) in 5% milk/TBST.  After incubation the
membrane was washed 4 – 5 times with TBST. The membrane was then incubated in a
proprietary chemiluminescent reagent (Western Lighting Plus, PerkinElmer Inc., Waltham,
MA) and developed on film (Eastman Kodak Company, Rochester, NY).  Films were then
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scanned into the ImageJ imaging software package (National Institutes of Health,
Bethesda, MD) for processing.
Electrophoresis Gel Analysis of MHC Isoforms in Skeletal Muscle Tissue:
Tissue Preparation: Bilateral spinotrapezius muscles were exteriorized, blotted, weighed,
snap-frozen in liquid nitrogen-chilled isopentane and stored at -80 °C until ready for
processing.  Individual, frozen muscles were first dehydrated for 1-2 hours before being
minced in microcentrifuge tubes using microscissors and microforceps.  Five hundred
microliters of MHC extract solution (0.3 M NaCL, 0.15 M Na2HPO4 and 10 mM EDTA)
per 1 mg of muscle tissue were added to the minced tissue before the samples were
homogenized in microcentrifuge tubes using a miniature pestle.  Homogenized samples
were then refrigerated at 4 °C for 60 minutes (stirred every 10 minutes) before being
centrifuged at 12,000 rpm for 10 minutes, yielding a final total protein concentration of
0.25 – 0.5 mg/mL. The supernatant was transferred to microcentrifuge tubes and stored at
-70 °C until ready for use and the pellet was discarded.
Electrophoresis Stock Solutions: The following stock solutions were prepared prior to
any electrophoresis experiments and stored for no more than one month at 4 °C, unless
otherwise noted:
68.16% Glycerol: 68.16 mL glycerol in 100 mL deionized water.
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29% Acrylamide-BIS : 14.21 g acrylamide and 0.29 g bis (N, N’-methylene-bis-
acrylamide) in 50 mL deionized water.  Solution was gravity filtered through Whatman #1
filter paper into a dark glass container and used immediately.
1.5 M Tris-HCl Base (pH 8.8): 9.085 g Tris in 50 mL deionized water.  Tris was initially
dissolved in 40 mL deionized water and pH adjusted to 8.8 with 6 N HCl before being
volumized to 50 ml with deionized water.
0.5 M Tris-HCl Base (pH 6.8): 3.94 g Tris in 50 mL deionized water.  Tris was initially
dissolved in 40 mL deionized water and pH adjusted to 6.8 with 6 N HCl before being
volumized to 50 ml with deionized water.
100 mM EDTA: 1.86 g EDTA in 50 mL deionized water.
10% Ethanol: 5 mL of absolute ethyl alcohol in 45 mL deionized water.
10% Sodium Docecyl Sulfate (SDS): 10 g SDS in 90 mL deionized water.  Solution stored
at RT.
Sample Buffer (2x Laemmli Sample Buffer): 12.5 mL 0.5 M Tris-HCl Base, 20 mL 10%
SDS, 10 mL glycerol, 2 mL 2-mercaptoethanol, 2.5 mL bromophenol blue dye (3.5 mg
bromophenol blue in 2.5 mL deionized water).  Solution was stored in a dark glass
container until ready for use.
10% Ammonium Persulfate: 0.050 g ammonium persulfate per 0.5 mL deionized water.
Solution was prepared immediately prior to electrophoresis experiment.
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Gel Electrophoresis Running Buffers: The following running buffers were prepared
immediately prior to electrophoresis experiments and stored at 4 °C until ready for same-
day use:
Upper Running Buffer (~380 mL required for gel electrophoresis): 100 mM Tris base, 150
mM glycine, 0.1% SDS and deionized water.
Lower Running Buffer (~1240 mL required for gel electrophoresis): 50 mM Tris base, 75
mM glycine, 0.05% SDS and deionized water.
Total Muscle Protein Assay: Protein concentration standards from BioRad Laboratories
(Hercules, CA) were prepared according to proprietary instructions before being placed in
a microtiter plate for analysis.  The total protein concentration of each sample was
determined using the Gel-Pro Analyzer software (Media Cybernetics, Inc., Bethesda, MD).
After total protein concentration of each sample was determined, samples were diluted as
necessary to a final concentration of 0.25 mg/mL by the addition of MHC extract solution.
Gel Preparation and Casting: Stock solutions were removed from the refrigerator and
brought to room temperature.  The 8% separating gel was prepared by combining the
following components:  8.803 mL 68.16% glycerol, 5.520 mL 29% acrylamide-BIS, 2.667
mL 1.5 M Tris base, 2 mL 1 M glycine, 0.8 mL 10% SDS and 0.2 mL 10% ammonium
persulfate.  The mixture was thoroughly mixed and then degassed for 15 minutes and 10
µL tetramethylethylenediamine (TEMED; BioRad Laboratories, Hercules, CA) was added.
The solution was drawn into a disposable pipette, taking care not to introduce air bubbles,
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then slowly injected into a casting stand.  A layer of 10% ethanol was then carefully placed
on top of the separating gel, which was allowed to set for at least 30 minutes while the 4%
stacking gel was prepared (4.494 mL 68.16% glycerol, 1.380 mL 29% acrylamide-BIS, 1.4
mL 0.5 M Tris base, 0.4 mL 100 mM EDTA, 0.4 mL 10% SDS, 1.821 mL deionized water
and 0.1 mL 10% ammonium persulfate, all from BioRad Laboratories, Hercules, CA).  The
mixture was swirled and degassed for 15 minutes.  Meanwhile, the 10% ethanol was
poured off and glass gel casting plates carefully dried with Whatman #1 filter paper (GE
Healthcare, Waukesha, WI).  The well comb was placed at an angle between the glass
plates of the casting stand and 5 µL of TEMED was added to the degassed solution.  The
solution was then drawn into a disposable pipette, taking care not to introduce air bubbles,
and slowly injected into the casting stand.  The well comb was tapped gently to remove
any trapped air bubbles and the stacking gel was allowed to set for at least one hour.
Muscle Sample Preparation: Muscle samples and the pre-stained standard were removed
from the freezer and allowed to thaw during preparation of the stacking gel.  After
thoroughly mixing the thawed samples, 30 µL of muscle sample was combined with 25 µL
of sample buffer to yield a final sample concentration of 0.225 mg/mL.  Samples were then
boiled for 5 minutes and allowed to cool to RT.
Assembly of Electrophoresis Apparatus: After being allowed to set, gels were removed
from the casting stand, clamped to a central cooling core and placed in the lower buffer
chamber.  A small amount (~10 mL) of upper running buffer was placed into the upper
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buffer chamber and the well comb was slowly removed.  Wells were gently cleaned with
upper running buffer using a 5 mL syringe with a blunted 23 gauge needle.  Gel loading
pipette tips were used to load 20-40 µL of muscle sample (depending on concentration)
into each well, excluding the first and last well for quality control purposes.  The pre-
stained standard was loaded into two wells.
Running Conditions: After the assembly was placed in the refrigerator, the upper and
lower buffer chambers were filled with their respective buffers. After bubbles were gently
removed from the bottom of the glass plates, 400 µL of 2-mercaptoethanol was added to
the upper buffer chamber.  Electrodes were secured to the apparatus and a constant voltage
of 275 V and maximum current of 25 mA was applied for 90 minutes.  The maximum
current was then reduced to 15 mA/gel and the gel was allowed to run for 29 hours.
Processing: Gels were carefully scanned into a computer using the GelPro imaging
software package (Media Cybernetics, Inc., Bethesda, MD) for later image processing.
Statistics:
Rat subject morphological data, fiber geometric data, MHC gel optical density data, mean
capillary density scores, mean scores for degree of NOS1 staining and Western blot protein
content comparisons between strains were all analyzed by the unequal variance t-test.
Fiber geometric data, MHC gel optical density data and Western blot protein content
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comparisons within one strain of rat were carried out with the Welch ANOVA and the
Tukey-Kramer HSD post-hoc test was used to determine differences between means.  For
all analyses, differences were considered significant at p < 0.05.  Values presented in the
text, tables and graphs are means ± standard error (SE).
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RESULTS
Rat Subjects
Summary statistics for the rat subjects used in the immunohistochemical (IHC), Western
blot (WB) and myosin heavy chain (MHC) gel electrophoresis experiments are presented
in Tables 1 and 2.  SHR subjects used in IHC experiments were slightly, but significantly,
older than their WKY controls.  No statistically significant difference was found between
the ages WKY and SHR rat subjects used in WB and gel electrophoresis experiments.  As
expected, mean invasive mean arterial blood pressures (MAP) of SHR subjects used in
IHC experiments were found to be significantly higher than those of their age-matched
WKY controls.  Interestingly, mean invasive MAPs for WKY and SHR WB subjects were
not significantly different.  As mentioned in the Materials and Methods section, non-
invasive hemodynamic data were also collected.  However, these data were meant as a
semi-quantitative measure to monitor and confirm the degree of hypertension in SHR
subjects prior to tissue harvesting and are therefore not being presented, in deference to the
more accurate invasive measurements.  No statistically significant difference was found
between the heart rates of age-matched WKY and SHR rat subjects used in IHC, WB and
gel electrophoresis experiments. Unexpectedly, SHR subjects used in IHC, WB and MHC
gel electrophoresis experiments weighed significantly more than their age-matched WKY
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controls.  There were no significant differences in the weights of either the left or right
spinotrapezius muscles of the WKY and SHR subjects used in WB and gel electrophoresis
experiments.
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Table 1 SUMMARY STATISTICS FOR RAT SUBJECTS USED IN IHC
EXPERIMENTS
Strain n Age (Weeks) Body Weight (g) Invasive MAP
(mmHg)
Heart Rate
(Beats/ Min)
WKY 5 16.0 ± 0.074 274.1 ± 2.43 102.0 ± 2.30 384.6 ± 8.05
SHR 5 16.4 ± 0.0* 344.9 ± 1.36* 155.9 ± 4.47* 376.4 ± 7.56
Values are mean ± SE. * = Significantly different from age-matched WKY, p < 0.05
Table 2 SUMMARY STATISTICS FOR RAT SUBJECTS USED IN WB AND MHC
GEL ELECTROPHORESIS EXPERIMENTS
Strain n Age
(Weeks)
Body
Weight
(g)
Invasive
MAP
(mmHg)
Heart Rate
(Beats/Min)
Left
Spinotrapezius
Muscle Weight
(g)
Right
Spinotrapezius
Muscle Weight
(g)
WKY 4 17.0 ±
0.0
268.8 ±
0.4
114.4 ±
4.5
402.0 ± 19.5 0.087 ± 0.011 0.087 ± 0.011
SHR 4 17.0 ±
0.0
363.0 ±
0.7*
134.8 ±
10.8
403.0 ± 13.7 0.091 ± 0.015 0.103 ± 0.011
Values are means ± SE. * = Significantly different from age-matched WKY, p < 0.05
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Myosin Heavy Chain (MHC) Determinations
MHC Fiber Type Distributions:
Examples of Images Collected: Figures 1 and 2 below are representative images of Type I
fiber staining in WKY and SHR subjects, respectively.  Note the lines designating the area
of interest (AOI) within the image (scale bar = 50 µm).  Figures 3 and 4 are examples of
Type IIA fiber staining in WKY and SHR subjects, respectively.  Note the lines
designating the AOI within the image (scale bar = 50 µm).  Figures 5 and 6 are examples
of IIB fiber staining in WKY and SHR subjects, respectively.  Note the lines designating
the AOI within the image (scale bar = 50 µm).  Negative control images were too dim to
be adequately imaged.
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Figure 1. Representative image of Type I fiber staining in WKY rat.
Scale bar = 50 µm
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Figure 2. Representative image of Type I fiber staining in SHR.
Scale bar = 50 µm
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Figure 3. Representative image of Type IIA fiber staining in WKY rat.
Scale bar = 50 µm
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Figure 4. Representative image of Type IIA fiber staining in SHR.
Scale bar = 50 µm
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Figure 5. Representative image of Type IIB fiber staining in WKY rat.
Scale bar = 50 µm
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Figure 6. Representative image of Type IIB fiber staining in SHR.
Scale bar = 50 µm
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Fiber Type Distribution Statistics: Table 3 describes the distribution of positive-staining fibers
as the number of positive fibers of each fiber type divided by total number of positive and
negative (i.e., non-stained) fibers for that fiber type in WKY and SHR subjects. Table 4
describes the total cross-sectional area of positive fibers of each type divided by the total cross-
sectional area of all positive and negative fibers of that type in WKY and SHR subjects.
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Table 3 SUMMARY STATISTICS FOR PERCENT FIBER POPULATION
(FIBER COUNT BASIS)
Fiber
Type
WKY
2
WKY
3
WKY
4
WKY
5
Mean for
WKY ± SE
SHR
4
SHR
5
Mean
for SHR
± SE
Type I 40.9 47.8 32.5 42.1 40.8 ± 3.2 55.3 * 55.3
Type
IIA
42.9 25.4 25.5 27.1 30.2 ± 4.2 19.4 19.8 19.6 ±
0.1
Type
IIB
22.5 12.1 31.8 17.0 20.9 ± 4.2 23.2 * 23.2
Values are percentages. *Insufficient Type I and IIB fiber count data for SHR 5 to
complete calculation of fiber population.
Table 4 SUMMARY STATISTICS FOR PERCENT FIBER POPULATION
(TOTAL CROSS-SECTIONAL AREA BASIS)
Fiber
Type
WKY 2 WKY 3 WKY 4 WKY 5 Mean for
WKY ± SE
SHR 4 Mean for
SHR ±
SE
Type I 53.6 51.9 30.1 39.7 43.8 ± 5.5 43.6 43.6*
Type
IIA
34.8 21.2 15.3 20.5 23.0 ± 4.2 9.9 9.9*
Type
IIB
46.5 20.0 42.2 22.9 32.9 ± 6.7 48.0 48.0*
Values are percentages. *Insufficient data exist to calculate mean ± SE.
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Analysis of MHC Isoform Expression by Gel Electrophoresis:
Figures 7 and 8 below are representative images of the MHC protein band images obtained
from the electrophoretic gel. Note that there was some degradation in quality when the
images were enlarged for insertion into this document.  No statistically significant
difference in the amount of Type I, IIa or IIb MHC protein, determined by gel
electrophoresis and expressed as the intensity of the protein band, was detected between
WKY and SHR subjects, as noted in Table 5.  However, when levels of Type I, IIa and IIb
MHC protein were compared within the WKY subjects, there was significantly less IIa
MHC protein than Type I and IIb MHC protein (Table 6 and Fig. 9).  There was no
statistically significant difference between the intensities of Type I, IIa and IIb MHC
isoforms in SHR subjects (Fig. 10).  Type IId/x MHC protein was not detected in the gel
electrophoresis experiment in either strain.  Migration sequence of MHC isoforms was
determined based on observations by Talmadge and Roy (1993).
73
Table 5 SUMMARY STATISTICS FOR INTENSITY OF MHC ISOFORM
BANDS IN WKY VS. SHR SUBJECTS
Strain n Type I Type IIA Type IIB
WKY 4 37.0 ± 3.8 18.7 ± 1.2 44.3 ± 3.8
SHR 4 37.5 ± 2.1 25.9 ± 3.1 36.6 ± 5.0
Values are means ± SE (arbitrary units).  No statistically significant difference detected
between strains (α = 0.05).
Table 6 SUMMARY STATISTICS FOR INTENSITY OF MHC ISOFORM
BANDS WITHIN STRAINS
Strain MHC Isoform Mean ± SE
WKY (n = 4)
Type I 37.0 ± 3.8%*
Type IIa 18.7 ± 1.2%†
Type IIb 44.3 ± 3.8%*
SHR (n = 4)
Type I 37.5 ± 2.1%
Type IIa 25.9 ± 3.1%
Type IIb 36.6 ± 5.0%
Isoforms not connected by the same symbol are significantly different, p < 0.05
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Figure 7. Representative image of MHC protein bands in WKY rat.
Figure 8. Representative image of MHC protein bands in SHR.
IIa
IIb
I
IIa
IIb
I
~200 kDa
~200 kDa
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Figure 9. MHC Intensity for Type I vs. IIa vs. IIb in WKY (Mean ± SE, α = 0.05).
The three MHC isoform intensity means were compared using the unequal variance F-test
and found to be significantly different.
[(F(2,9) = 17.3), p-value = 0.0008].
Isoforms not connected by the same symbol are significantly different.
*
†
*
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Figure 10. MHC Intensity for Type I vs. IIA vs. IIB in SHR (Mean ± SE, α = 0.05).
The three MHC isoform intensity means were compared using the unequal variance F-test
and not found to be significantly different.
[(F(2,9) = 3.23), p-value = 0.0878].
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MHC Fiber Geometric Data
Fiber Cross-sectional Area: Mean cross-sectional areas of Type I fibers from each strain
were compared and WKY fibers were demonstrated to be significantly larger than SHR
fibers (Table 7).  Mean cross-sectional areas of Type IIA fibers were compared between
strains and not found to be significantly different.  Mean cross-sectional areas of Type IIB
fibers were compared and SHR fibers were demonstrated to be significantly larger than
WKY fibers (Table 7).
Fiber Perimeter: Mean perimeters of WKY Type I fibers were found to be significantly
greater than those of SHR subjects (Table 7).  There were no significant differences
between the mean perimeters of WKY and SHR Type IIA fibers (Table 7).  However,
mean perimeters of SHR Type IIB fibers were found to be significantly greater than those
of age-matched WKY control subjects (Table 7).
Minimum Fiber Diameter: The mean minimum diameters of WKY Type I fibers was
found to be significantly greater than that of SHR subjects.  The mean minimum diameters
of WKY and SHR Type IIA fibers were not found to be significantly different (Table 7).
The mean minimum diameter of SHR Type IIB fibers was found to be significantly greater
than that of age-matched WKY control subjects (Table 7).
Maximum Fiber Diameter: The mean maximum diameter of WKY Type I fibers was
found to be significantly greater than that of SHR subjects (Table 7). The mean maximum
diameters of WKY and SHR Type IIA and IIB fibers were not found to be significantly
different (Table 7).
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Min/Max Fiber Diameter Ratio: No statistically significant differences were detected in
the minimum/maximum fiber diameter ratios for Type I, IIA and IIB fibers between the
WKY and SHR strains (Table 7).
Minor Elliptical Fiber Diameter: The mean minor elliptical diameter of WKY Type I
fibers was found to be significantly greater than that of SHR subjects (Table 8). There was
no significant difference between the mean minor elliptical diameters of WKY and SHR
Type IIA fibers (Table 8). The mean minor elliptical diameters of SHR Type IIB fibers
were found to be significantly greater than those of age-matched WKY control subjects
(Table 8).
Major Elliptical Fiber Diameter: The mean major elliptical diameter of WKY Type I
fibers was found to be significantly greater than that of SHR subjects (Table 8). The mean
major elliptical diameters of WKY and SHR Type IIA fibers were not found to be
significantly different (Table 8). The mean major elliptical diameter of SHR Type IIB
fibers was found to be significantly greater than that of age-matched WKY control subjects
(Table 8).
Minor/Major Elliptical Diameter Ratio: No statistically significant differences were
detected in the minor/major fiber elliptical diameter ratios for Type I, IIA and IIB fibers
between the WKY and SHR strains (Table 8).
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Table 7 SUMMARY STATISTICS FOR BASIC MHC FIBER GEOMETRIC
DATA
Strain MHC
Fiber
Type
n Minimum
Fiber
Diameter
Maximum
Fiber
Diameter
Min/Max
Diameter
Ratio
Fiber
Perimeter
Fiber
Cross-
sectional
Area
WKY
Type I 331 36.3 ± 0.6 66.7 ± 1.2 0.57 ± 0.01 177.9 ±
3.0
2079.3 ±
61.0
Type
IIA
203 27.3 ± 0.5 50.9 ± 1.1 0.56 ±0.01 134.4 ±
2.5
1204.2 ±
39.5
Type
IIB
181 42.1 ± 0.8 83.4 ± 2.0 0.53 ± 0.01 226.4 ±
5.1
3006.7 ±
115.7
SHR
Type I 227 32.3 ± 0.7* 61.3 ± 1.5* 0.55± 0.01 162.5 ±
4.0*
1767.2
± 74.8*
Type
IIA
129 28.6 ± 0.9 51.7 ± 1.3 0.56 ± 0.01 136.4 ±
3.3
1283.8
± 58.2
Type
IIB
101 47.8 ± 1.6* 90.1 ± 3.2 0.55 ± 0.01 251.7 ±
8.8*
3865.7
± 249.2*
Values are means ± SE in µm [except for cross-sectional area (in µm2) and ratio (unitless)].
n = number of fibers measured. * = Significantly different from age-matched WKY,
p < 0.05.
80
Table 8 SUMMARY STATISTICS FOR MHC FIBER ELLIPTICAL DATA
Strain MHC
Isoform
n Minor Fiber
Elliptical
Diameter
Major
Elliptical
Diameter
Minor/Major Elliptical
Diameter Ratio
WKY
Type I 327 34.9 ± 0.5 71.7 ± 1.4 0.51 ± 0.01
Type IIA 202 27.1 ± 0.5 53.9 ± 1.1 0.52 ± 0.01
Type IIB 180 39.1 ± 0.7 93.7 ± 2.3 0.44 ± 0.01
SHR
Type I 223 32.3 ± 0.6* 65.6 ± 1.8* 0.52 ±  0.01
Type IIA 129 28.4 ± 0.8 54.2 ± 1.4 0.53 ± 0.01
Type IIB 101 43.9 ± 1.3* 104.1 ± 3.8* 0.44 ± 0.01
Values are means ± SE in µm [except ratio (unitless)]. n = number of fibers measured.
* = Significantly different from age-matched WKY, p < 0.05.
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Alkaline Phosphatase Staining to Reveal Capillary Endothelium
Capillary density and the number of capillaries around a fiber (CAF) were calculated for
both strains of rats using the procedures outlined in the Materials and Methods section.
There was no significant difference in either capillary density or mean CAF between the
two strains (Table 9). Figures 11 and 12 below are examples of alkaline phosphatase
staining to reveal capillary endothelium in WKY and SHR subjects, respectively.  Scale
bars = 50 µm.
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Table 9 SUMMARY STATISTICS FOR CAPILLARITY
Metric Strain Observations Mean ± SE
Capillary Density (capillaries/mm2) WKY 12 224.3 ± 23.0
SHR 11 200.1 ± 16.1
Capillaries Around a Fiber (CAF) WKY 41 2.51 ± 0.224
SHR 30 2.87 ± 0.208
Observations for: 1) Capillary Density = regions of interest examined, 2) CAF = number of
fibers examined.
No statistically significant difference detected between strains for either metric (α = 0.05).
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Figure 11. Representative image of alkaline phosphatase staining for capillary
endothelium in WKY rat.
Scale bar = 50 µm
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Figure 12. Representative image of alkaline phosphatase staining for capillary
endothelium in SHR.
Scale bar = 50 µm
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Co-localization Studies of Nitric Oxide Synthase Isoforms
Nitric Oxide Synthase 1 (NOS1): Figures 13 and 14 below are representative images of
NOS1 staining in WKY and SHR subjects, respectively.  Scale bar = 50 µm.  The
numerically labeled fibers were determined also to contain the Type I MHC isoform by
serial tissue sample sectioning and staining.  The degree of NOS1 / Type I MHC staining /
co-localization was determined using the following numerical scale:
0 = absent 1 = light staining 2 = intermediate staining 3 = dark staining
The image grading instruction sheet given to all seven observers can be found in Appendix
A.  There was no significant difference in the practice mean numeric grading scores among
observers (Appendix B).  Summary statistics for the practice grading session are presented
in Appendix C.  As noted, observers #4, #6 and #7 detected statistically significant
differences in the degree of NOS1 staining between experimental WKY and SHR subjects
(Table 10).  Visual inspection revealed sarcolemmal and sub-sarcolemmal NOS1 staining
in nearly all of Type I examined.  However, some fibers demonstrated a diffuse and
somewhat granular staining pattern, which often varied in intensity between fibers in the
same image.
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Table 10 SUMMARY STATISTICS FOR EXPERIMENTAL NUMERIC
STAINING GRADES
Observer Strain Mean Numeric Score ± SE
1 WKY (n = 3) 1.59 ± 0.07
SHR (n = 4) 1.64 ± 0.08
2 WKY (n = 3) 1.32 ± 0.08
SHR (n = 4) 1.51 ± 0.07
3 WKY (n = 3) 1.48 ± 0.06
SHR (n = 4) 1.64 ± 0.06
4 WKY (n = 3) 1.17 ± 0.08
SHR (n = 4) 1.58 ± 0.08*
5 WKY (n = 3) 1.83 ± 0.09
SHR (n = 4) 1.81 ± 0.10
6 WKY (n = 3) 1.23 ± 0.09
SHR (n = 4) 1.58 ± 0.09*
7 WKY (n = 3) 0.85 ± 0.06
SHR (n = 4) 1.18 ± 0.06*
All observers graded a total of 81 WKY fibers and 72 SHR fibers. n = number of animals.
* = Significantly different from age-matched WKY, p < 0.05.
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Figure 13. Representative image of NOS1 staining in WKY rat.
Scale bar = 50 µm
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Figure 14. Representative image of NOS1 staining in SHR.
Scale bar = 50 µm
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Nitric Oxide Synthase 2 (NOS2): Figures 15 and 16 are representative images of NOS2
staining in WKY and SHR subjects, respectively.  Scale bar = 50 µm.  The numerically
labeled fibers were determined also to contain the Type IIA and IIB MHC isoforms (as
determined by staining with a proprietary primary antibody that recognizes both Type IIA
and IIB MHC isoforms) by serial tissue sample sectioning and staining.  Inspection of the
entire image series revealed evenly distributed staining that appeared somewhat punctate
with little variation in the degree of staining between individual fibers and with no
discernable difference between rat subject strains.  It was therefore determined that, unlike
the NOS1 staining, NOS2 staining analysis would not benefit significantly from further
semi-quantitative analysis by a group of individual observers.
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Figure 15. Representative image of NOS2 staining in WKY rat.
Scale bar = 50 µm
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Figure 16. Representative image of NOS2 staining in SHR.
Scale bar = 50 µm
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Nitric Oxide Synthase 3 (NOS3): Figures 17 and 18 below are representative images of
NOS3 staining in WKY and SHR subjects, respectively.  Scale bar = 50 µm.  Inspection of
the entire image sequence revealed uniform, punctate-like NOS3 staining within muscle
fibers, regardless of rat subject strain being examined.  Most striking was the intense
staining of the arteriolar endothelium and, to a lesser extent, the venular endothelium.  This
intense level of staining raises several questions which will be addressed in the Discussion
section.
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Figure 17. Representative image of NOS3 staining in WKY rat.
Scale bar = 50 µm
Intense arteriolar staining is denoted by arrow in center of image.
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Figure 18. Representative image of NOS3 staining in SHR.
Scale bar = 50 µm
Intense arteriolar staining is denoted by arrow in center of image.
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Co-localization of NOS3 and Alkaline Phosphatase (AP) Staining for Capillary
Endothelium:
Data from the twenty three pairs of images collected from both WKY and SHR subjects
revealed that 46.6% of the NOS3 “spots” detected co-localized with a corresponding AP
“spot” in the next serial WKY rat spinotrapezius muscle section.  In the SHR subjects,
32.3% of the NOS3 “spots” detected co-localized with a corresponding AP “spot” in the
next serial tissue section.  Of the NOS3 “spots” that lacked a corresponding AP “spot,”
98% of those NOS3 “spots” were located between fibers in WKY subjects, as opposed to
within a fiber, while only 55% of those NOS3 “spots” were located between fibers in the
SHR subjects (Table 11).
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Table 11 SUMMARY STATISTICS FOR CO-LOCALIZATION OF NOS3
AND ALKALINE PHOSPHATASE STAINING FOR CAPILLARY
ENDOTHELIUM
Strain Number
of AP
spots
detected
Number of
Correspond
ing NOS3
spots
detected
% co-localization
of AP and NOS3
spots
Number of
spots on NOS3
image without
corresponding
AP spot
Number
of NOS3
spots
between
fibers
% of
NOS3
spots
between
fibers
% of
NOS3
spots
within
fiber
WKY 163 76 46.6 97 95 98 2
SHR 158 51 32.3 80 44 55 45
97
Western Blot Analysis of NOS Isoforms:
Figure 19 below contains representative images of α-tubulin, NOS1, NOS2 and NOS3
protein bands from Western blots conducted to determine NOS expression in
spinotrapezius muscle tissue samples.  WKY protein samples occupy lanes 1 – 4, while
SHR protein samples occupy lanes 5-7.  In the first blot, no significant differences were
found in the amount of NOS1, NOS2 or NOS3 between strains (Table 12 above).
“Intensity” values are the ratios of the NOS Western blot intensity value divided by the
corresponding α-tubulin value. There was significantly more NOS1 than either NOS2 or
NOS3 in both WKY and SHR subjects used in the first blot (Fig. 20). Although the
phosphorylated forms of both NOS1 and NOS3 were probed for, their corresponding
protein bands were too faint to be sufficiently imaged in the first blot (data not shown) and
were therefore not probed for in the second blot.
The second blot revealed significantly less NOS3 in SHR subjects versus their
WKY controls (Table 13).  Although there is relatively more NOS1 than both NOS2 and
NOS3 in both strains, unequal variance statistical analysis failed to detect statistically
significant differences in NOS1, NOS2 and NOS3 within subjects from either strain in the
second blot (Fig. 21).
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Table 12 SUMMARY STATISTICS FOR NOS1-3 EXPRESSION IN WKY
AND SHR STRAINS AS DETERMINED BY WESTERN BLOT #1
Strain NOS Isoform n NOS/α-tubulin Intensity Ratio
WKY
NOS1 4 2.14 ± 0.20
NOS2 4 0.960 ± 0.06
NOS3 4 0.936 ± 0.02
SHR
NOS1 3 2.18 ± 0.05
NOS2 3 0.915 ± 0.01
NOS3 3 0.940 ± 0.10
Values are means ± SE (unitless). n = number of animals.
No statistically significant differences in NOS1-3 expression detected between strains (α =
0.05).
Table 13 SUMMARY STATISTICS FOR NOS1-3 EXPRESSION IN WKY
AND SHR STRAINS AS DETERMINED BY WESTERN BLOT #2
Strain NOS Isoform n NOS/α-tubulin Intensity Ratio
WKY
NOS1 3 8.48 ± 2.13
NOS2 3 2.32 ± 0.77
NOS3 3 0.43 ± 0.02
SHR
NOS1 3 17.7 ± 9.0
NOS2 3 3.58 ± 1.57
NOS3 3 0.11 ± 0.05*
Values are means ± SE (unitless). n = number of animals.
* = Significantly different from age-matched WKY, p < 0.05.
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Figure 19. Representative protein band images of A) α-tubulin (52 kDa), B) NOS1  (165
kDa), C) NOS2 (130 kDa) and D) NOS3 (140 kDa) in Western blots
WKY SHR
A)
B)
C)
D)
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Isoforms not connected by the same symbol are significantly different, p > 0.05
Figure 20. NOS1 vs. NOS2 vs. NOS3 in WKY and SHR in Blot #1 (α = 0.05).
The means were compared using an unequal variance F-test and found to be significantly
different in both strains.
WKY = [(F(2, 4.26) = 15.6), p-value = 0.0110]; SHR = [(F(2, 2.71) = 218.5), p-value =
0.0010]
*
† †
*
† †
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Figure 21. NOS1 vs. NOS2 vs. NOS3 in WKY and SHR in Blot #2 (α = 0.05).
The means were compared using an unequal variance F-test and found not to be
significantly different in either strain.
WKY = [(F(2, 2.67) = 8.13), p-value = 0.0732]; SHR = [(F(2, 2.67) = 3.49), p-value =
0.1799]
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DISCUSSION
Summary of Results:
Overview: As best as can be determined, this is the first study to characterize the fiber
type population, geometric morphology, capillarity and nitric oxide synthase (NOS)
expression of the spinotrapezius muscle of the spontaneously hypertensive rat (SHR) and
make direct comparisons to its normotensive control, the Wistar-Kyoto rat (WKY) rat.
Fiber Type Populations: Percent fiber type population by fiber count from this study
indicates the spinotrapezius muscle of the WKY is comprised of 40.8% Type I fibers,
30.2% Type IIA fibers and 20.9% Type IIB fibers.  Using the same methodology, it was
determined that the SHR is comprised of 55.3% Type I fibers, 19.4% Type IIA fibers and
23.2% Type IIB fibers.  Percent fiber population by cross-sectional area (CSA) from this
study indicates the spinotrapezius muscle of the WKY is comprised of 43.8% Type I
fibers, 23.0% Type IIA fibers and 32.9% Type IIB fibers.  Using the same methodology, it
was determined the SHR is comprised of 43.6% Type I fibers, 9.9% Type IIA fiber and
48.0% Type IIB fibers.  The fiber population percentages by CSA for the SHR add up to
more than 100% (101.5%), but because of the variability of the individual fiber type
percentages, the total is not significantly different from 100%.  Considering the drawbacks
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of using CSA to determine fiber populations, there is a reasonable explanation for this
discrepancy which will be discussed later in this chapter.
Morphometry of Fibers:
Basic Fiber Geometry: Results from this study indicate that minimum and maximum fiber
diameters, fiber perimeter and CSA of Type I fibers are all significantly smaller in the
SHR compared to the WKY control.  Conversely, minimum fiber diameter, fiber perimeter
and CSA of Type IIB fibers are significantly larger in the SHR compared to the WKY.
There were no statistically significant differences in any basic fiber geometry metric
detected in Type IIA fibers between strains.  Furthermore, no significant differences in the
minimum/maximum fiber diameter ratio were detected between strains.
Elliptical Fiber Geometry: Results from this study indicate that minor and major elliptical
diameters of Type I fibers in the SHR were significantly smaller than those of their age-
matched WKY normotensive controls.  Conversely, the minor and major elliptical
diameters of Type IIB fibers in the SHR were significantly larger than those of their WKY
normotensive controls.  Finally, no significant differences in the minor/major elliptical
fiber diameter ratio were detected between strains.
Capillarity: No statistically significant differences in either capillary density or average
number of capillaries around a fiber (CAF) were detected between SHR and WKY strains.
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NOS Expression:
Immunohistochemistry (IHC): Three of seven blinded observers detected significantly
more NOS1 in Type I fibers of SHR subjects compared to their noromotensive controls.
NOS2 appeared to be evenly distributed within Fast (Type IIA and IIB) muscle fibers in a
punctate manner, with little variation in the degree of staining between individual fibers
and with no discernable difference between rat subject strains.  NOS3 appeared to be
distributed in a uniform, punctate-like manner within muscle fibers, regardless of rat
subject strain being examined, with strikingly intense staining of the arteriolar endothelium
and to a lesser extent, the venular endothelium.
Western blot: The first of two blots detected no significant differences in the amount of
NOS1, NOS2 or NOS3 between strains.  However, there was significantly more NOS1
than either NOS2 or NOS3 in both WKY and SHR subjects used in the first blot.  The
second blot revealed significantly less NOS3 in SHR subjects versus their WKY controls
while unequal variance statistical analysis failed to detect statistically significant
differences in NOS1, NOS2 and NOS3 within subjects from either strain.
Animal Subjects:
Age: The mean age of the SHR rat subjects used in the IHC experiments was found to be
significantly older than that of the WKY subjects (Table 1).  Although the difference was
minimal, it may explain why those SHR subjects weighed significantly more than their
WKY controls.  Previous authors have reported three stages in the development of
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hypertension in the SHR:  rising of blood pressures at 4-8 weeks, arrival of peak pressure
at 14-18 weeks and the stabilization of blood pressure at ≥ 24 weeks (Prickar et al. 1994,
Bortolotto et al. 1999).  Therefore, since all components of this study required
experimental animals (SHRs) with fully manifested hypertension, young adult animals
aged approximately 16-17 weeks were selected.  It is important to note that Harlan
Laboratories, Inc., the supplier of the animals used in this study, cautions customers that
normal blood pressure values for its animals may vary between colonies and differ from
published literature.  Harlan also suggests that further variation may be introduced by the
customer’s own pressure monitoring techniques.  These suggestions should be kept in
mind during the interpretation of blood pressure data presented here.
Mean Arterial Pressure (MAP): Since MAP is approximately equal to cardiac output
(CO) multiplied by total peripheral resistance (TPR), an elevated MAP would suggest an
increase in either CO, TPR or both.  Furthermore, TPR may be increased due to
vasoconstriction of the proximal arterioles and/or a decrease in available vascular
pathways – especially in the microvessels, a phenomenon known as rarefaction.  The
capillarity component of this study allowed for direct investigation of possible rarefaction
in the skeletal muscle microvascular bed of the SHR and those results will be discussed
later in this chapter.  However, in order to ensure the SHR subjects used in this study
demonstrated fully manifested hypertension, both invasive and non-invasive MAP data
were collected.  The invasive MAPs of the SHR subjects used in IHC experiments were
indeed significantly elevated above those of their WKY controls. No significant difference
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in the invasive MAPs of WKY and SHR subjects used in the WB and MHC gel
experiments was detected (Table 2).  This result is best explained by the difference in MAP
observations between the two strains (WKY = 9 and SHR = 18) and the resultant SE for
the statistical analysis (Table 2).  The difference in number of observations is due to the
shorter duration of the surgical procedures to remove the spinotrapezius muscles from
WKY versus SHR subjects. As mentioned previously in the Results section, non-invasive
hemodynamic data were collected as a semi-quantitative measure to monitor and confirm
the degree of hypertension in SHR subjects prior to tissue harvesting and therefore will not
be discussed further.
Classification of Fibers:
Fiber Type Population Distributions By:
Fiber count vs. CSA: Before discussing the fiber type population distribution results, it is
important to note that insufficient data were collected from SHR subjects to allow for
statistical comparison of fiber populations.  There are several reasons for this deficiency.
The quality of SHR tissue sections was variable.  Because serial sectioning was required to
carry certain comparisons in this study (e.g., NOS1 / Type I fiber co-localization), if one
tissue section was of poor quality, the entire sequence needed to be re-sectioned and the
quantity of tissue available for sectioning became a concern.  However, even if tissue
specimen quality appeared sufficient at the time of sectioning, preparation artifact often
appeared during or after processing of the tissue.  The primary reason for the insuffici
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ent amount of data from three of four SHR subjects was that, upon visual inspection under
brightfield microscopy, the fiber-typing tissue specimens either did not allow for sufficient
discrimination of positive and negative fibers (required for determination of percent
population by fiber count) and/or fiber boundaries were not clearly discernable (required
for determination of percent population by CSA) and image acquisition from these slides
was not pursued.  Therefore, the data collected in this phase of the study must be
interpreted with caution.
Considering percent fiber populations as determined by CSA, the determination
that Type IIA fibers comprise 9.9% of the spinotrapezius (ST) muscle in the SHR is in
good agreement with Delp and Duan’s (1996) determination that Type IIA fibers comprise
7% of the ST in adult male Sprague-Dawley rats.  Likewise, this study’s findings that Type
I fibers constitute 43.8% of the fiber population (and 40.8% by fiber count) in the WKY
and 43.6% in the SHR, and thatType IIB fibers comprise 32.9% of the ST in WKY
subjects by CSA are also in good agreement with Delp and Duan’s findings (1996). Delp
and Duan’s 1996 study of the composition and size of the spinotrapezius muscle from
adult male Sprague-Dawley rats demonstrated that type IIB fibers make up 35 ± 5% of the
total muscle mass, type IID/X fibers 17 ± 3%, type IIA fibers 7 ± 3%, and type I fibers 41
± 2%. The CSA across all muscles was 4,248 ± 263µm2 for type IIB fibers, 2,895 ± 468
µm2 for type IID/X fibers, 1,448 ± 133 µm2 for type IIA fibers, and 1,265 ± 73 µm2 for
type I fibers (Delp and Duan 1996).
According to the CSA data collected for this study, 48% of the SHR ST is
comprised of Type IIB fibers.  This is in agreement with the widely and long-held notion
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that skeletal muscle tissue from hypertensive subjects contains a higher percentage of fast-
twitch fibers than normotensive controls (Juhlin-Dannfelt et al. 1979, Frisk-Holmberg et
al. 1988, Bortolotto et al. 1999, Benbachir-Lamrini et al. 1990 and 1993, Lewis et al.
1994).  However, this phenomenon has been primarily observed in humans and other
groups have found contradictory results in rodents (Gray 1988, Atrakchi et al. 1994).  In
fact, if percent population by fiber count is considered, this study found that 55% of the ST
in the SHR is comprised of Type I fibers and 23.2% are Type IIB, results that are in
contrast to the results rendered by CSA analysis.  Given that tissue from only one SHR was
studied, the SHR fiber population results presented here need to be interpreted with great
care.  This point is further illustrated by the fact that the fiber population percentages by
CSA for the SHR add up to more than 100% (101.5%), but this result is tempered by the
observed variability of fiber type composition.  This result can likely be explained by the
fact that a trackball mouse was used to collect data from images under the ImagePro
software package as it was the only type of mouse compatible with the PC being used for
this portion of the project.  The trackball may have introduced error in the fiber outlines
and, in aggregate, caused the discrepancy in total fiber population by CSA in the SHR.
By both fiber count and CSA methodologies, there were a greater percentage of
Type IIA fibers in both SHR and WKY rats than predicted by Delp and Duan (1996).  This
result must be interpreted with great care for the following two reasons.  First, muscle
fibers are capable of transforming from one fiber type extreme to another in response to
numerous stimuli including altered functional demands, changes in neural input and
hormonal signals (Pette and Staron 1990, Delp and Duan 1996).  Second, Delp and Duan
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warn that because skeletal muscle fibers are capable of such extreme transformations,
grouping of fibers into distinct types may be artifactual and that the muscle sizes,
composition and oxidative potentials reported in their paper may only be applicable for rats
of the same strain, age and gender, thereby rendering any comparisons herein between
WKY and SHR problematic (Delp and Duan 1996).  If any or all of these stimuli were
present in the SHR and/or WKY rats used in this study, it is possible the Type IIA fibers
counts obtained here are merely temporary and not generalizable to the lifespan of the
animal.
Totaling the WKY and SHR ST fiber population percentages presented in Tables 3
and 4 (except SHR fiber population by CSA analysis as noted above) produce totals that
are less than 100%.  This “shortfall” likely represents the contribution of IID/X fibers in
the ST muscle that were not specifically probed for in this project.  The decision not to
pursue these fibers is primarily because it was never a goal of this study to exhaustively
characterize the fiber type composition of the ST muscle in the WKY and SHR strains.  At
the inception of the project the goal of the IHC experiments was merely to determine the
general distribution of NOS in the ST in both WKY and SHR animals.  As the literature
was reviewed it became clear that knowledge of the slow- vs. fast-twitch fiber composition
of subjects’ ST muscles was important.  It was decided that since tissue sections were
being probed with antibodies against the various NOS isoforms, a similar approach would
be used to detect Type I (“Slow”) and Type IIA and Type IIB (“Fast”) fibers using
established antibodies.  As the project progressed the aims of the study changed and an
additional minor aim was to determine the populations of Type I, IIA and IIB fibers in the
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ST muscle since antibodies against Type IIA and IIB MHC isoforms were readily available
and their proper working dilutions for this application were known.  Since Type I, IIA, IIB
and IID/X fiber types comprise the fiber type population of the ST, the IID/X percent
population can be determined by exclusion if the Type I, IIA and IIB fiber populations are
known.
MHC Isoform Content via Gel Electrophoresis: IId/x MHC protein was undetectable via
gel electrophoresis in either strain.  This is in agreement with the determination that IID/X
fibers would constitute only 0.3 – 8.1% of the fiber population in the WKY (by CSA and
fiber count, respectively) and 2.1% of the population in the SHR (by fiber count).  It is also
in agreement with a portion of Bortolotto et al.’s (1999) findings where the group failed to
detect any MHC IId/x protein in the soleus muscle of 16-week old WKYs.  However, that
group found significantly more MHC IId/x protein in soleus muscles of 16- and 24-week
old SHRs compared to age-matched WKY controls (Bortolotto et al. 1999).  This study’s
finding that there was significantly less Type IIa MHC protein than either Type I or IIb
protein in the ST of WKY rats is in agreement with Delp and Duan’s finding that Type IIA
fibers comprised only 7% of the ST fiber population of adult male Sprague-Dawley rats
and Bortolotto et al.’s finding that the MHC IIa isoform comprised only 9.2% of the MHC
content in 16-week old WKYs (Delp and Duan 1996, Bortolotto et al. 1999).  It bears
repeating, however, that these results must be interpreted with caution since the ST is a
postural muscle while the soleus is a muscle of locomotion with different metabolic
demands.
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Fiber Morphometry:
Indices of Fiber Shape: Previous work has determined that skeletal muscle fibers are not
circular, as was often assumed, but rather more elliptical or hexagonal in shape and that a
fiber’s shape is relatively independent of its size (Barnard et al. 1971, Peter et al. 1972,
Romanul 1974, Aquin et al. 1973, Sjøgaard 1982, Sullivan and Pittman 1984, Bennett et
al. 1991).  These findings are important for accurate modeling of O2 transport and
consumption, nitric oxide (NO) formation and transport and for drawing conclusions from
capillarity data.  Results from this study are in agreement with these prior findings as noted
by the fact that the two indices of fiber shape, minimum/maximum diameter ratio and
minor/major elliptical diameter ratio, were in the range of 0.53 – 0.57 and 0.44 – 0.53,
respectively, indicating the fibers studied were not circular in shape, since the diameter
ratio would be 1.00 for a circular cross-section.
Minimum Fiber Diameter: This study’s finding that SHR Type I fibers had smaller
minimum diameter and Type IIB fibers had larger minimum diameters than their age-
matched WKY controls suggests a preference for the glycolytic metabolic pathway in the
animals’ ST muscle profile and is in agreement with the notion that skeletal muscle tissue
from hypertensive subjects contains a higher percentage of fast-twitch fibers than
normotensive controls, as discussed above (Juhlin-Dannfelt et al. 1979, Frisk-Holmberg et
al. 1988, Bortolotto et al. 1999, Benbachir-Lamrini et al. 1990 and 1993, Lewis et al.
1994).
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Maximum Fiber Diameter: As with minimum fiber diameter, this study’s finding that
SHR Type I fibers had significantly smaller maximum diameters than their age-matched
WKY controls again suggests a preference for the glycolytic metabolic pathway in the
animals’ ST muscle profile.  However, caution is warranted with this interpretation as SHR
Type IIB fiber maximum diameter was not found to be significantly larger than that of the
WKY controls.
Cross-sectional Area (CSA): Type I fibers in the SHR had smaller cross-sectional area and
Type IIB fibers had larger cross-sectional area than their age-matched WKY controls.  This
finding is in agreement with Sullivan and Pittman’s (1984) finding that fast-glycolytic
(FG) fibers had larger CSA than both slow oxidative (SO) and fast oxidative-glycolytic
(FOG) fibers from the same muscle (Sullivan and Pittman 1984).
Perimeter: Type I fibers in the SHR had smaller perimeters and Type IIB fibers had larger
perimeters than their age-matched WKY controls.  These results are consistent with the
other morphometric data presented above and again suggest that the glycolytic metabolic
pathway may be favored in the ST of SHR animals compared to their age-matched,
normotensive controls.
Capillarity:
Two measures of capillarity were obtained in this study.  The first was capillary density,
expressed as the number of capillaries per square millimeter of tissue cross-section.  The
second was the number of capillaries around a fiber (CAF).  These measures are important
since capillaries are the primary “exchange” vessels in the circulation and their frequency
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of occurrence is related to oxygen (O2) and nutrient supply, as well as metabolic waste
removal.  Type I and IIA fibers have the greatest metabolic (O2) requirements, while Type
IIB fibers, the largest of the three fiber types studied here, have a lower O2 demand but a
greater need for removal of glycolytic metabolites.
Despite the significant differences in minimum fiber diameter, maximum fiber
diameter, fiber perimeter and cross-sectional area detected in SHR subjects compared to
their age-matched WKY controls, there were no significant differences in either mean
capillary density or CAF between strains.  These results are similar to those obtained by
Plyley and Groom (1975) from rat gastrocnemius and soleus muscles (Plyley and Groom
1975).  For reasons discussed earlier in this chapter, these data must be interpreted with
caution since the ST is a postural muscle while the gastrocnemius and soleus are muscles
of locomotion and whose fiber type distributions, and therefore capillarity profiles, likely
vary between strain and by age.  Additionally, Plyley and Groom (1975) did not identify
the age or strain of rat they used in their study (other than to say they were adult animals).
Despite these caveats, Plyley and Groom (1975) reasonably suggest that the higher O2
demands of oxidative skeletal muscle tissue are met by a reduction in fiber size rather than
an increase in microvessel (capillary) density  and this study’s finding that Type I fibers in
the SHR are significantly smaller (by CSA and minimum/maximum diameter) than their
WKY controls lends support to this notion (Plyley and Groom 1975).
The present findings are also in conflict with numerous reports of microvascular
rarefacation in SHRs aged 4-18 weeks of age (Prewitt et al. 1982, Smith et al. 2004,
Sabino et al 2008).  For example, Greene et al. (1990) found an approximate 14%
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reduction in the capillary density in the ST muscle of 12-week old SHRs compared to age-
matched WKY controls (Greene et al. 1990).  It is possible that these results represent a
lack of anatomical or structural rarefaction of the capillary bed, a phenomenon discussed
by Prewitt et al. (1982) in which there
is no discernable reduction in the number of microvessels in a particular vascular bed, but
rather a reduction in the number of microvessels open to flow of red blood cells (RBCs)
(Prewitt et al. 1982).  The methodology used in this study, however, did not allow for
determination of microvessel patency (i.e., the microvascular bed was not perfused under
pressure to ensure patency of the vessels).  The results of a future study that employs such
methodology in subjects of the same strains and ages as those used in this study would
likely yield interesting and useful information.
Another possibility is that there is indeed rarefaction of the microvascular bed
present in the SHR ST muscle samples studied here, except it has manifested itself in
reduced arteriolar density vs. capillary density.  Prewitt et al. (1982) observed this
phenomenon in the gracilis muscles of SHRs aged 16-18 weeks, suggesting it is reasonable
to believe that a similar process is occurring in the SHRs used in the present study.
Tissue shrinkage is a known problem with many histological procedures and it is
unknown if or to what degree tissue used in this study may have shrunk during processing.
Future studies could better control for this by placing reference marks a known distance
apart on the harvested tissue before freezing and then remeasuring after freezing.
Furthermore, only one observer conducted the capillary counts presented in this study.
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Future studies may benefit from having several independent observers conduct vessel
counts in order to reduce the possibility of error or bias in the final results.
NOS Expression via IHC:
Three NOS isoforms were probed for in WKY and SHR ST muscle sections via
IHC, including neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2) and
endothelial NOS (eNOS or NOS3).  Although both nomenclatures can be found in the
current literature, this discussion will use the NOS1/2/3 nomenclature to minimize possible
confusion about location of the particular isoform being discussed.
Isoform Location by Fiber Type: The body of NO and NOS literature is immense and
conflicting reports regarding the occurrence of NOS in skeletal muscles abound (to say
nothing of visceral muscle and other tissues).  It is also important to note that this study is,
as best as can be determined, the first of its kind to investigate NOS distribution in the ST
muscle of adult WKY and SHR subjects.  Therefore, generalization of the results presented
here to other rat strains, muscle groups, muscle types and other mammalian species must
be made with caution.  With these caveats in mind, the results obtained here are in
agreement with several reports in the literature.
NOS1 in Type I skeletal muscle fibers in the ST: A goal of the present study was to
determine, in a semiquantitative manner, to what degree NOS1 co-localizes with Type I
skeletal muscle fibers in WKY and SHR ST tissue (using several independent observers as
outlined in Materials and Methods and Appendix A) and to describe the staining
distribution of the enzyme in the muscle fiber.  In their 1996 and 2000 studies, Frandsen et
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al. found NOS1 near the sarcolemma and in the cytoplasm of human vastus lateralis
muscle from healthy subjects (Frandsen et al. 1996 and 2000).  It should be noted that in
the 2000 Frandsen study the group graded the degree of NOS staining in their samples in a
manner similar to what was done in the present study, although details about who graded
the staining and how this was done is not discussed in the article.  In 1996, Capanni et al.
described NOS1 staining in the gracilis muscle of 6- and 24-month old Wistar rats as
“granular,” and in 2001, Punkt et al. detected NOS1 in Type I skeletal muscle fibers of 6-
month old male Wistar rats and described the staining as granular, diffused throughout the
cytoplasm and near the sarcolemma, descriptions that nicely compliment the results of the
present study (see Fig. 14;Capanni et al. 1996, Punkt et al. 2001).  The Punkt group also
determined the degree of NOS staining in a manner similar to that of Frandsen et al. (2005)
and the present study.  However, like the Frandsen group, Punkt et al. did not provide a
detailed description of their semi-quantification methods in their article.  A
subsarcolemmal NOS1 staining pattern similar to that described by Punkt et al. (2001) was
also detected by Gath et al. (1996) in guinea pig muscle and Buchwalow et al. (2005) in
adult male Wistar rat quadriceps tissue (Gath et al. 1996, Buchwalow et al. 2005).
As best as can be determined, this is the first study to attempt to semi-quantify the
degree to which NOS1 co-localizes with Type I MHC fibers in WKY and SHR rat strains.
Therefore, comparisons between the current findings with those in established literature
must be made with caution.  Furthermore, given that fewer than half of the observers
detected significantly more NOS1 in SHR vs. WKY subjects, the present results must also
be interpreted with caution.  However, it is conceivable that the apparent increase in NOS1
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expression in the ST of SHR subjects is a compensatory mechanism for a deficiency in
NOS3 in the same tissue, as detected by the second Western blot conducted in this study.
This notion is supported by Biecker et al.’s (2004) finding that NOS1 mRNA levels are
partially maintained in aortae of NOS3 deficient mice (Biecker et al. 2004).
NOS2 in Type IIA/B fibers: Another goal of the present study was to determine to what
degree NOS2 co-localizes with Type IIA/B skeletal muscle fibers in WKY and SHR ST
tissue and to describe the staining distribution of the enzyme in the muscle fiber.
Examination of the NOS2 images collected from Type IIA/B fibers known to co-localize
with NOS2 revealed a spotty, punctate staining pattern throughout the cytoplasm.  These
observations are in close agreement with Gath et al. (1996), who observed markedly
similar staining patterns in guinea pig skeletal muscle tissue (the authors did not specify
which muscle(s) they used in their study) (Gath et al. 1996).  Interestingly, Gath et al.
(1996) detected NOS2 in intracellular structures in “specific pathogen-free” animals,
raising the intriguing possibility that NOS2 may, in fact, be constitutively active in some
species (Gath et al. 1996).  Punkt et al. (2002) also demonstrated NOS2 staining in rat
hindlimb muscles in a manner similar to what is described here (Punkt et al. 2002).
However, the immunoreactivity was stronger in tissue from young (embryonic and 21-day
old) subjects than from older (21 and 75-day old) subjects and was primarily co-localized
with Type IIA muscle fibers (Punkt et al. 2002).  As mentioned in the Results section,
inspection of the entire NOS2 image series revealed little variation in the degree of staining
between individual fibers and with no discernable difference between rat subject strains.  It
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was therefore determined that, unlike the NOS1 staining, NOS2 staining analysis would
not benefit significantly from further semi-quantitative analysis using individual observers.
This study’s finding agrees with the notion proposed by Gath et al. (1996) that
NOS2 demonstrates either a higher level of activity or is constitutively active in skeletal
muscle tissue from more than one species, as Gath’s study used guinea pigs (Gath et al.
1996).  Like Gath et al., the staining pattern seen here is consistent with the sarcoplasmic
reticulum and/or transverse tubule system, and future studies could probe more specifically
for the co-localization of NOS2 with these structures in WKY and SHR ST tissue (Gath et
al. 1996).  Further interpretation of this particular result is difficult because the presence of
the NOS2 enzyme does not necessarily equate to NO production in direct proportion to the
concentration of enzyme present.  This quandary highlights the need for more accurate
methods of determining in vivo NO concentrations than currently exist.
NOS3 Association with Capillary Endothelium: As with NOS1 and NOS2, another goal of
this study was to determine if NOS3 was localized solely in the endothelium of WKY and
SHR capillaries by staining for NOS3 and capillary endothelium in serial sections.  No
attempt to investigate co-localization with a particular fiber type was made in this study
since prior reports suggest NOS3 expresses a heterogeneous pattern within muscle fibers
that does not differ systematically between fiber types (Reid 1998).
Frandsen et al. (1996) reported NOS3 immunoreactivity in the endothelium of
larger vessels as well as microvessels of healthy human vastus lateralis tissue (Frandsen et
al. 1996).  This is in agreement with this study’s findings that arterioles and venules, in
addition to capillaries, also stained intensely for NOS3.  Gath et al. (1996) made a similar
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observation of their NOS3 staining patterns in guinea pig skeletal muscle tissue.  Again,
however, the authors did not specify which muscle(s) they used in their study (Gath et al.
1996).  Interestingly, Punkt et al. (2001) found diffuse or granular staining throughout the
cytoplasm of 6-month old Wistar rat skeletal muscle tissue, which they semi-quantified
(using a scale similar to the one used in this study) as ranging from “very weak” to
“strong” (Punkt et al. 2001).  Although semi-quantification of NOS3 was not conducted in
this study, a strikingly similar granular staining pattern in the ST muscle of SHR subjects
was observed in the present results (see Figure 18).
Given the intensity of the NOS3 staining in arteriolar and venular endothelium
described here, the question arises:  “What might these patterns imply about potential
sources of NO in these vessels?”  One significant implication is that NOS3 is expressed in
other structures in addition to the endothelial cells in these vessels.  There is evidence for
this notion in the literature.  Villanueva and Giulivi (2010) reviewed literature
investigating the cellular and sub-cellular locations of NOS isoforms and reported a
number of studies in the literature that suggest NOS3 is located in a variety of tissues
across species, including eosinophils, epithelial cells of human nasal mucosa, fibroblasts,
gastrointestinal mucosae, hepatocytes, lymphocytes, neutrophils, skeletal muscle,
syncytiotrophoblasts of human planceta and type II alveolar cells (Villanueva and Giulivi
2010).  However, the most likely explanation comes from Buchwalow et al.’s 2008 study
in which they found evidence for all three NOS isoforms, and strong staining for NOS3 in
particular, in both intimal and medial cells of thoracic aorta, mesenteric artery and
pulmonary artery sections from adult male Wistar rats that had been completely denudated
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of endothelial tissue (Buchwalow et al. 2008).  These finding correlate nicely with this
study’s results and offer some of the strongest evidence for NOS3 outside the endothelium
of the vessels studied here.
This finding is particularly exciting because there is still considerable debate in the
literature regarding many aspects of the physiology of NO in vivo.  Numerous unanswered
questions remain, including “How far does NO spread in biologically relevant
concentrations,” “What is the profile of NO release over time from different sources,” and
“How is it captured to elicit biological responses?” (Hall and Garthwaite 2009).  While the
goal of this study was not to provide definitive answers to these questions, the fact that a
previous finding has been confirmed is important.  In particular, this finding suggests
another potential source of NO that lies a distance from the vessel lumen where red blood
cells (RBCs), and in particular, hemoglobin, are known as substantial sinks for NO in vivo
(Pacher et al. 2007).  It is estimated that even with hemoglobin sequestered in erythrocytes,
they scavenge so much NO that the endothelium must produce an estimated 100 nM NO to
achieve the 5-10 nM NO concentrations required by smooth muscle tissue containing
soluble guanylyl cyclase (sGC), the primary target of NO in vivo (Pacher et al. 2007).
Clearly, the notion that smooth muscle is incapable of expressing NOS must be re-
examined.  Future studies further exploring the extent to which NOS may truly be
expressed in smooth muscle tissue are clearly indicated.
Co-localization of NOS3 staining with alkaline phosphatase (AP) staining for capillary
endothelium: As best as can be determined, this is the first time this particular comparison
of NOS3 IHC and AP staining has been made in the ST of WKY and SHRs.  Therefore,
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conclusions from the data must be drawn with caution.  The discrepancy between the
percent co-localization results for WKY and SHR strains likely has more to do with
limitations of the staining techniques employed.  The NOS3 and AP staining protocols did
not require dehydration of the tissues specimens.  Therefore, these slides were mounted in
an aqueous medium (see Materials and Methods) which is prone to air bubble artifact.
Furthermore, it is possible that the seal between glass slide and coverslip was breached at
some point between slide processing and viewing on the microscope, allowing air bubbles
to contaminate the tissue and/or allowing the tissue to desiccate and shrink.  While care
was taken not to use slides with obvious artifact, the possibility of artifact cannot be
discounted.
If the cautious assumption that the NOS3 “spots” detected in this portion of the
study do indeed correspond to capillary endothelium, the finding that 98% of the of NOS3
“spots” without a corresponding AP “spot” lie between muscle fibers is in agreement with
previously published results from striated hamster tissue (Bennett et al. 1991).  However,
as mentioned before, care must be taken when making such comparisons between strains.
Interestingly, the finding for SHR that 55% of the NOS3 “spots” lacking an AP corollary
were located within fibers coincides with the earlier finding that NOS3 appears in a
granular pattern within skeletal muscle fibers of SHR subjects.
Limitations of IHC Technique: Although IHC techniques have been steadily advancing in
recent years, limitations to the approach still exist.  Since the spinotrapezius muscle of the
rat is only ~500 µm thick, both muscles from each subject had to be extracted and then
folded one upon the other in order to provide the bulk necessary for cryostat sectioning.
122
This caused unavoidable gaps in and distortions to the tissue as it was submerged in
cryoprotectant medium and frozen.  The use of serial sectioning required that each section
in a particular series needed to be of comparable quality.  Therefore, if one section was
damaged during sectioning, the entire sequence needed to be re-sectioned.  Although care
was taken to prevent artifact (i.e., always ensuring the blade was sharp and temperature
settings were correct), it is not possible to completely rule out some degree of chatter or
tissue compression.
Biochemical supply vendors make it clear that final working concentrations of
antibody purchased for a particular application must be determined by the end user.
Although literature was reviewed to determine ideal initial concentrations to expedite
antibody dilution experiments, it soon became clear that many protocols had been highly
tailored and customized by the group performing the research and that these groups often
used antibodies that were unavailable for the current project.  Antibody concentrations
used in the NOS IHC portion of this study ranged from 1:50 (NOS3) to 1:2000 (NOS1),
suggesting the NOS3 antibody may be of lower quality due to the need for a higher
concentration to achieve demonstrable results.  Finally, all of the NOS antibodies used in
this project were polyclonal, so some degree of non-specific binding may have occurred.
In light of these drawbacks, all experiments were performed consistently under as identical
working conditions as possible, using fresh reagents to minimize introduction of artifact.
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NOS Expression via Western blot:
Expression of NOS isoforms: Greater-than-expected NOS2 protein expression levels in
Sprague-Dawley rat ST muscle tissue have been detected before by Western blot in this lab
(unpublished data).  Therefore, data from both blots performed for this study indicating
that all three isoforms are constitutively active at the protein level in WKY and SHR ST
muscle tissues, and that NOS1 is the predominant isoform, were not unexpected and in
accord with previous reports from several mammalian species (Gath et al. 1995,
Grozdanovic et al. 1995, Stamler and Meissner 2001, Buchwalow et al. 2005, Punkt et al.
2006 and 2008).
The finding that there was less NOS3 expressed in SHR subjects compared to their
age-matched controls in the second blot was expected insofar as there is much literature to
support the notion that there may be less NOS3 expressed and/or diminished levels of
bioavailable NO to effect vasodilation in SHRs with manifested hypertension (Malinsky et
al. 1993, Cuevas et al. 1996, Dubois 1996, Crabos et al. 1997, Sunano et al. 1996).
However, one hypothesis driving this study was that NOS3 expression would be increased
in the SHR vs. WKY.  This hypothesis was based on intriguing previous reports of
increased plasma nitrate levels (an index of the formation of NO in the rat) in adult male
Wistar rats and induction of NOS3 expression in canine coronary vascular tissue and on
reports that SHRs demonstrate generalized vasoconstriction and blood hyperviscosity (De
Clerck et al. 1980, Prewitt et al. 1992, Sessa et al. 1994, Nava et al. 1996).  It is possible
that the SHRs used in this study were still too young for the resultant vasculopathy of long-
standing hypertension to have been fully manifested, including the hypothesized
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upregulation of NOS3.  It is also possible that this NOS3 upregulation has already occurred
in other tissues (e.g., neural and renal) that were not studied in the current project.
Use of α-tubulin as loading control: Alpha-tubulin was selected as the loading control for
the Western blots in this study over the more commonly used β-actin based on a 1983
report from Farmer et al. which reported that changes in cell growth conditions and
interactions with extracellular matrix components may alter actin protein synthesis (Farmer
et al. 1983).  Furthermore, certain physiological conditions including, but possibly not
limited to, hypoxia and diabetes can alter GADPH expression levels, also making it an
unsuitable loading control for this study (Said et al. 2007).  Therefore, α-tubulin, another
commonly used loading control, was selected for use in this study as its expression has,
thus far, only been found to vary according to resistance to antimicrobial and antimitotic
drugs, neither of which the rat subjects used in this study were exposed to (Sangrajrang et
al. 1998, Prasad et al. 2000).
Consistency of Results between Blots: In the first blot, significantly more NOS1 than
NOS2 and NOS3 were detected within each strain, but no significant differences in NOS1-
3 expression were noted between strains.  The converse was true in the second blot; there
was significantly less NOS3 in SHR compared to age-matched WKY subjects; however,
no significant differences in NOS1-3 expression were detected within each strain.
Furthermore, comparison between Figures 20 and 21 demonstrates differences in NOS / α-
tubulin intensity ratio scales.  This is because the signal-to-noise ratio was much lower in
the second blot, possibly obscuring existing differences between isoform expression within
strains.  Given this lack of consistency of results between blots, any interpretation of the
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data they yield should be made with great care and repetition of the blots is likely
warranted in the future.
Overall Conclusions:
Purpose of Study: This study sought to fill in gaps in the literature regarding the
distribution and modulation of NOS in postural skeletal muscle tissue of hypertensive rat
subjects.  A long-term goal of this project is to use the distribution data gathered here in
computational models that describe NO distribution in postural skeletal muscle.  These
models take into account the numerous and detailed reactions that produce NO to predict in
vivo NO concentrations in skeletal muscle tissue.  Accurate and complete data of this type
are crucial as input for these models, since the model results may presently be the best
representatives of in vivo NO concentrations, perhaps even better than direct in vivo
measurements with microelectrodes and indirect measurements via fluorescent indictors.
This is because the accuracy and validity of such measurements were called into question
in a comprehensive review by Hall and Garthwaite (2009).  The review noted
inconsistencies in the literature regarding physiological in vivo NO concentrations, which
range from femtomolar to hundreds of micromolar, and a glaring lack of consensus
between groups making these measurements (Hall and Garthwaite 2009).  Despite the
drawbacks of current in vivo measurement tools currently available, the need for in vivo
measurements to confirm or refute the predictions made by computational models remains.
Therefore, it is hoped that the data presented here will aid in the development of more
accurate in vivo measurement techniques for NO.
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Important Connections: Given the volume of literature on the topic, there is little doubt
that NO is clearly an important signaling molecule in vivo and that it exerts numerous
biological effects in a number of systems and tissues, including the microvasculature.
Much is already known about the regulation of the NOS enzymes that create NO in a
tightly controlled manner (see reviews by Alderton et al. 2001, Kone et al. 2003).
However, the most relevant interactions that can be addressed by this study are those
between NO and the tissues responsible for oxygen (O2) supply and delivery, since every
cell in an organism requires O2 to survive.
To review briefly, this study has demonstrated the presence of significantly larger
(by CSA) Type I MHC fibers in SHR subjects (Table 7).  Given the highly oxidative
nature of these fibers, it may be inferred that the presence of increased amounts of
hemoglobin and myoglobin may act as NO sinks, potentially reducing the concentrations
of bioavailable NO in the SHR to effect vasodilation, which in turn would reduce
bioavailable O2 for consumption by the mitochondria.  Furthermore, since it is known that
NO inhibits mitochondrial respiration, and results presented here demonstrated
significantly more NOS1 in Type I fibers of the SHR (Table 10), it is possible the
oxidative capacity of these fibers is abrogated somewhat by the (presumably) increased
NO concentration (Stamler and Meissner 2001).  It bears repeating that assumptions about
NO activity based solely on NOS enzyme concentration must be made with great care.
Finally, there are numerous reports that contractile function of mammalian skeletal muscle
tissue is modulated by NO (for review see Stamler and Meissner 2001).  However, there
appears to be a lack of consensus about the exact nature of these effects as they depend on
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the muscle preparation being studied, the experimental protocol, NO concentration and the
NO source (Stamler and Meissner 2001).  Although there are reports to the contrary,
Kobzik et al. (1994) reported an inverse correlation between force generation in rat soleus,
diaphragm and extensor digitorum longus muscles and NOS activity and suggested that
NOS activity contributes to the intrinsic differences in force generation by Type I and Type
II fibers (Kobzik et al. 1994, Stamler and Meissner 2001).  Although measurements of
force production by the ST muscle were not made for the current study, results from a
future study in light of the NOS distribution results collected here could further elucidate
the exact nature of the relationship between NOS expression and skeletal muscle type in
hypertension.
Another conclusion that may be drawn from the current results is that NOS
expression appears to be altered in hypertension as noted by significantly more
NOS1expression in SHR Type I skeletal muscle fibers (Table 10), significantly less NOS3
expression in the ST muscle compared to WKY controls (Table 13) and an apparently
constitutively active NOS2 isoform that is expressed to the same relative degree in both
strains (Figs. 15 and 16, Tables 12 and 13).  The exact consequences remain to be
elucidated by the future studies both already discussed and outlined below, as well as by
computational models of in vivo NO concentrations for which the data presented here can
be used.
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Recommendations for Future Studies:
In addition to the suggestions for future work already mentioned in this chapter,
studies exploring the potential co-localization of Type IIA/B/D/X MHC fibers with NOS1
could be carried out using confocal microscopy.  These would allow for fluorescent
labeling of more than one antigen of interest in a single tissue section and eliminate the
need for serial sections, which are somewhat problematic for the reasons discussed above.
Further delineation of the role of NO in O2 supply and demand (VO2) could be determined
with in vivo experiments on WKY and SHR spinotrapezius muscles, similar to those
conducted by Smith et al. (2004) in the presence of NOS inhibitors and/or NO donors.
Such studies may also benefit from determination of NOS activity in the subjects used via
plasma nitrite, nitrate and L-citrulline concentrations to allow for more accurate
correlations of NOS enzyme expression and actual NO production in vivo.  Finally, given
the variability between the Western blots performed for this project, it may be beneficial to
conduct the blots again under identical circumstances to further confirm or refute the
conclusion that NOS3 expression is indeed diminished in the ST of the SHR.
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APPENDIX A
Image Grading Instruction Sheet
Name:____________________________
IMAGE GRADING INSRUCTIONS
- There are three (3) practice slides and 14 experimental slides.
- Total time to grade all slides, including the practice slides, should be about 30
minutes.  Although you may take as much time as you require, please try to grade
all slides in ~30 minutes.
- You can advance to a new slide or review a previous slide by clicking the “l<” and
“>l” buttons. DO NOT use the scrolling wheel on the mouse!  This will change the
image size and magnification.
- Grade only fibers that have a corresponding line on that slide’s score sheet.
For example:
Slide 3
0 = absent 1 = light 2 = intermediate 3 = dark
Fiber # NOS1 Staining Grade
1 0 1 2 3
2 0 1 2 3
3 0 1 2 3
4 0 1 2 3
5 0 1 2 3
7 0 1 2 3
**Note the gap between fiber #5 and #7!
- You may change your staining grade for any fiber at any time.
- If you cannot determine a particular fiber’s boundary, please do not hesitate to ask
for assistance.
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- All images have been filtered, processed and equalized; however, DO NOT
compare slides to one another. Grade fibers based on what you see just in that
slide.
- Consider the entire fiber when deciding on a staining score.
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APPENDIX B
Mean NOS 1 / Type I Fiber Numeric Staining Scores by Observer in Practice (WKY)
subjects (α = 0.05).  The means were compared using the unequal variance F-test and not
found to be significantly different.  [(F(6, 34.1) = 1.55, p-value = 0.19)
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APPENDIX C
Summary Statistics for Practice Numeric Staining Grades
Observer Number of Fibers
Graded
Mean Score ± SE
1 12 1.42 ± 0.23
2 12 1.25 ± 0.22
3 12 1.58 ± 0.29
4 12 1.42 ± 0.26
5 12 1.33 ± 0.19
6 12 1.17 ± 0.21
7 12 0.75 ± 0.18
No statistically significant differences between observers’
scores was detected (α = 0.05).
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